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ABSTRACT 
 This thesis attempts to answer the question of  “what is the significance of abnormal 
cortical excitability studies in movement disorders?”  Remarkably similar findings 
have been reported in Parkinson's disease (PD) and Stiff-man syndrome (SMS), the 
subjects of the studies contained in this thesis, despite these conditions manifesting 
with widely different clinical manifestations, one with hypokinetic and the other 
hyperkinetic movement problems.   
In SMS patients, cortical excitability studies were undertaken using the threshold 
tracking transcranial magnetic stimulation (TMS) along with measures of spinal 
excitability and anti-GAD antibodies as well as reported clinical measures in previous 
drug studies.  Remarkably, there was significant reduction in SICI despite most of the 
patients still being on benzodiazepines at the time of testing with dissociation between 
the cortical, spinal and clinical as well as plasma levels of anti-GAD antibodies.  The 
results suggest that spinal hyperexcitability and muscle stiffness and spasms are 
unlikely to be simply due to cortical disinhibition of spinal circuits. 
In PD patients, cortical excitability parameters measured with threshold tracking TMS 
was correlated with objective measures of bradykinesia and rigidity.  Relatively 
consistent findings were obtained with significantly reduced short intracortical 
inhibition (SICI) and intracortical inhibition (ICF) which appeared to be dependent on 
disease severity as well as plasma levodopa level.  Most significant findings were 
found in patients who had been on levodopa carbidopa intestinal gel (LCIG), a proven 
therapy against motor fluctuations and dyskinesia in advanced stages of the disease.  
In this group of patients who had been on LCIG therapy for more than 12 months, 
there was lack of decrement in hand tapping speed despite marked reduction in 
   viii 
plasma level of levodopa which was matched by significantly reduced SICI.  The 
results raise the possibility of restoration of the long duration effect of levodopa, 
perhaps related to sustained continuous dopaminergic therapy.  However, these 
patients displayed mild-moderate dyskinesia which might have influenced the results 
and the alterations in SICI in this setting require further evaluation.  
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Chapter 1 Transcranial magnetic stimulation and 
Parkinson’s disease: Insights into pathophysiology 
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1.1  INTRODUCTION 
Parkinson’s disease (PD) is a prototypical basal ganglia disorder with cardinal motor 
features of tremor, bradykinesia and rigidity [1].  There is mounting evidence that 
altered oscillatory activity in the basal ganglia-thalamo-cortical loop is central to the 
pathophysiology, which has been shown to correlate with rigidity and bradykinesia [2, 
3].  It is recognised that bradykinesia is not primarily the result of deficit in the motor 
cortex given that the movements elicited by direct stimulation of the motor cortex are 
the same whether the stimulus is given when patients are in the “off” state or “on” 
with dyskinesia [4].  However, the motor cortex is the final output pathway of the 
basal ganglia motor circuitry and thus understanding its contribution to the 
pathophysiology of Parkinson’s disease could provide further insights into the motor 
manifestations of the disease and carry potential therapeutic implications.  
Transcranial magnetic stimulation (TMS) is a robust method of interrogating the 
functions of the motor cortex and its circuitry and it has been extensively applied in 
PD, with reports of abnormalities in various parameters of motor cortical excitability, 
thereby suggesting involvement of the motor cortex in the disease pathophysiology 
[5-7].  
 
Significantly, based on the understanding that altered motor cortical excitability is a 
feature of PD and that plastic changes in excitability can be induced in the motor 
cortex with repetitive transcranial magnetic stimulation (rTMS) [8-11], a growing 
number of studies has explored the effect of applying rTMS as a therapeutic measure 
although to date only transient improvements in motor function have been reported 
[12, 13].   
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TMS studies in PD have produced mixed results and their significance remains 
uncertain, particularly in regards to the relationship between the excitability changes 
and clinical manifestations of PD.  The difficulty in unravelling the role of cortical 
excitability changes in PD pathophysiology arises from several factors related to the 
disease and technical factors.  With respect to disease related factors, the fact that PD 
is associated with impairments in a number of motor domains, including muscle tone 
and movement scaling, i.e. rigidity and bradykinesia, which are further complicated 
by the development of dyskinesia and motor fluctuations related to dopaminergic 
therapy, create a significant challenge in dissecting out the relationship between 
cortical excitability changes and impairments in individual motor domains.   A major 
limitation of cortical excitability studies reported thus far is that they do not allow 
definite conclusions to be drawn regarding whether the reported abnormalities are 
primarily due to the underlying disease or secondary to compensatory changes in the 
brain in an attempt to optimise motor performance or even still medications.   
 
The present review will firstly focus on the mechanism of generation of TMS 
parameters and critically analyse the reported changes in PD.  It will then consider the 
way in which these have contributed to the current understanding of PD 
pathophysiology and highlight areas of interest for further research. 
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1.2 SINGLE-PULSE TMS AND INSIGHTS INTO MOTOR CORTEX 
PHYSIOLOGY 
A standard single-pulse TMS involves exciting a network of motor cortical neurons 
and recording over the contralateral hand muscle, usually first dorsal interosseous 
(FDI) or abductor pollicis brevis (APB) muscle.  Single-pulse TMS provides basic 
information about the functions of the corticomotoneuronal system, with the main 
parameters being motor threshold (MT), motor evoked potential (MEP), and cortical 
silent period (CSP). 
 
1.2.1 Motor threshold 
Motor threshold reflects of how readily a group of cortcomotoneurons can be excited.  
It is a measure of the excitability of individual neurons and their local density [14-16] 
and similarly, the density of corticomotoneuronal projections onto the spinal motor 
neuron [17-19].  In addition, MT may also be a biomarker of cortical neuronal 
membrane excitability [20-22], whereby pharmacological blockade of voltage-gated 
sodium channels increases MT [23], while glutamate excitoxicity reduces MT [24].  
MT may be defined as the minimum stimulation intensity required to generate an 
MEP response of 50µV in the target muscle in 50% of the trials, using the constant 
stimulus technique [15, 25].  The more recently described threshold tracking 
technique on the other hand defines MT as the stimulus intensity required to elicit and 
maintain a target MEP response of 0.2 mV [26].  Of significance, MT correlates 
strongly with ability to perform independent (fractionated) finger movements as tested 
with finger tapping and pegboard dexterity, suggesting that MT is a clinically relevant 
measure [27].  
 
    
5 
In PD, mixed but generally consistent findings have been reported.  Several studies 
have reported reduced MT, both at rest (resting motor threshold, RMT) and during a 
weak voluntary muscle contraction (activated motor threshold, AMT) [28, 29] while 
others have reported normal thresholds [5, 7, 30-33].  This discrepancy likely arises 
from several factors, most significant of which is the fact that until recently there has 
been a lack of consensus in defining the parameters of TMS.  In particular, MT has 
been variably defined, such that in some studies the target MT amplitudes differed by 
more than 100% [5, 7, 32, 34, 35].  Secondly, despite PD being a heterogeneous 
disorder, some studies failed to differentiate PD patients into subgroups based on 
disease severity and predominant motor manifestations, reporting averaged results 
from a small number of patients with widely different disease duration, e.g. disease 
duration ranging from 4 months to 20 years in one study [34, 36].   
 
Notably, several studies have reported normal RMT but increased AMT, consistent 
with the notion of relative failure of voluntary facilitation in PD [34], which has been 
postulated to be a possible cortical mechanism underlying the development of 
bradykinesia, i.e. volitional activation failure [37].  However, the relationship 
between stimulus intensity and response amplitude, i.e. Stimulation Response (SR) 
curve, has been reported to be steeper than normal when tested at rest in PD [34, 38]. 
The steeper SR curve implies that the distribution of cortical excitability is skewed 
towards higher values than normal, possibly as a compensatory mechanism that 
attempts to overcome slow recruitment of commands to move by making it easier to 
recruit activity from a resting state.  Of relevance, TMS studies in PD patients who 
have had deep brain stimulation (DBS) surgery have shown that RMT in OFF-DBS 
condition is not significantly altered by switching to ON-DBS state or administration 
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of dopamine agonist, apomorphine, despite clear improvements in motor function 
[39], suggesting that RMT is not related to motor performance in PD unlike in normal 
controls where MT correlates with fine finger movements, and hence that clinical 
manifestations of PD are not primarily the result of any deficit in the excitability of 
individual motor neurons and their local density. 
 
1.2.2 Magnetic Evoked Potential 
Magnetic Evoked Potential (MEP) amplitude reflects a summation of complex 
corticospinal volleys consisting of D (direct) and I (indirect)-waves onto the motor 
neurons [20, 40].  At threshold, TMS elicits I1 waves, with the frequency and 
amplitude of I waves increasing with higher stimulus intensities [40].  The MEP 
amplitude increases with higher stimulus intensities, thereby enabling the generation 
of a stimulus-response (SR) curve that follows a sigmoid function [41].  The slope of 
the SR curve reflects the motor cortex excitability [41].  As with motor thresholds, the 
MEP amplitude reflects the density of corticomotoneuronal projections onto motor 
neurons [42], although the neuronal population mediating MEP responses appears to 
be different to those mediating MTs.   
The MEP amplitude should be expressed as a percentage of the supramaximal 
compound muscle action potential (CMAP) response [25], thereby accounting for any 
lower motor neuron contribution and providing an insight into the percentage of the 
motor neurone pool activated in the MEP.  Normative values for the MEP/CMAP 
ratio demonstrate a large inter-subject variability thereby limiting the value of this 
measure for detecting abnormalities of the corticomotoneurons [15, 43].     
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Previous TMS studies have reported mixed findings in MEP amplitudes in PD 
patients.  A number of studies have reported significantly higher MEP amplitudes at 
rest [28, 29, 44], consistent with the notion of increased membrane excitability of 
cortical neurons in PD, while others have reported normal MEP amplitudes [5, 7, 34, 
45]. 
 
One plausible explanation for reduced MT and increased MEPs, is that the studies 
were contaminated by incomplete relaxation or tremor which can exert facilitatory 
effects on cortical neurons and spinal cord [46].  This problem can be overcome by 
undertaking the studies during a uniform weak voluntary muscle contraction, as this 
controls for unwanted muscle activation contaminating the results.  Indeed, a recent 
study in early drug naïve PD patients showed that average AMT was not different 
from that of normal controls although there was increased variability, with greater 
oscillations around an average value [47].  Further evidence comes from a study, 
which found no differences in MTs and MEPs between PD patients and normal 
controls when studies were performed while subjects were generating a 20% 
voluntary contraction [48].   
 
 
1.2.3 Cortical silent period (CSP) 
CSP is defined as interruption of voluntary electromyographic (EMG) activity in a 
target muscle following TMS of the contralateral motor cortex [49].  The CSP 
duration is measured from the onset of the MEP response to resumption of voluntary 
EMG activity [23, 49] and increases with stimulus intensity [49-51]. 
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The initial phase of the cortical silent period is mediated by inhibition of the spinal 
alpha motor neurons, while the contributing mechanism of the late part of CSP is not 
exactly known but GABAB receptor mediated cortical inhibition most likely plays an 
important role, as pharmacological activation of GABAB receptors leads to significant 
CSP lengthening [49, 50, 52-55].  Of further relevance, the CSP duration appears to 
be influenced by the degree of corticomotoneuronal projections onto motor neurons, 
being longest in intrinsic hand muscles [15]. 
 
Abnormalities of the CSP are well established in PD, with TMS studies documenting 
a reduction in CSP duration, a finding which is most prominent with TMS intensity 
set to near-maximal [6, 7, 31, 48].  The CSP duration is significantly shorter on the 
more affected side [6, 47], and correlates with more severe clinical dysfunction as 
measured by the Unified Parkinson’s Disease Rating Scale (UPDRS) [6].  Of further 
relevance, the CSP duration is shorter when PD patients are in the OFF-medication 
state, whereas the CSP duration lengthens in the ON-medication state when the motor 
function, as measured by finger tapping speed, has improved [56].  Taken together, 
TMS studies suggest that dysfunction of the GABAergic neurotransmitter system, 
acting via GABAB receptors, may contribute to the generation of motor impairment in 
PD.  
 
1.3 PAIRED PULSE TMS TECHNIQUES 
Motor cortex excitability can also be assessed by utilising paired-pulse TMS 
techniques in which a conditioning stimulus modulates the effect of a second test 
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stimulus [16].  Several different paired-pulse TMS techniques have been developed to 
date [15, 23, 26, 57], but all techniques utilise a subthreshold conditioning stimulus, 
which modulates the effects of a second test stimulus.  In PD research, short interval 
intracortical inhibition (SICI) and intracortical facilitation (ICF) have been most 
frequently utilised to assess the extent of cortical dysfunction.  
 
Short interval intracortical inhibition and ICF are best assessed by delivering a 
subthreshold conditioning stimulus at pre-determined time intervals prior to a 
suprathreshold test stimulus [26, 58-60].  In the early TMS paradigms [58, 60, 61], the 
conditioning and test stimuli were kept constant, and changes in the test MEP 
amplitude were evaluated, such that when the interstimulus interval (ISI) was set 
between 1-5 ms, the test response was inhibited (SICI), and   increasing the 
interstimulus interval to between 7 and 30 ms resulted in facilitation of the test 
response amplitude (ICF) [15].  A potential limitation of this “constant stimulus” 
technique related to marked variability in MEP amplitudes with consecutive stimuli 
that may be up to 200%, making it is difficult to discern whether changes in the MEP 
produced are secondary to a true change in cortical excitability or, alternatively, 
represent fluctuations related to the delivery of the test stimuli [59, 62].  In an attempt 
to overcome this limitation, a threshold tracking technique was developed, whereby 
a constant target MEP response (0.2 mV) was tracked by a test stimulus, such that 
SICI was heralded by higher and ICF by lower conditioning-test stimulus intensities 
[26, 57].  By setting a tracking target of 0.2 mV, located in a steep portion of the 
nonlinear SR curve [41], marked variability in MEP amplitudes translate to smaller 
changes in stimulus intensity, potentially overcoming this limitation and provides the 
added advantage of speeding up the recording process thereby allowing multiple 
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recordings to be made in quick succession.  Two physiologically distinct phases of 
SICI, a smaller phase at ISI ≤1 ms and a larger phase at ISI 3 ms, were identified by 
the novel technique [26, 57, 63, 64].   
 
Short interval intracortical inhibition and ICF originate at the level of the motor 
cortex, mediated by synaptic processes, a notion supported by studies assessing the 
effects of paired-pulse TMS on descending corticospinal volleys [60, 65].  
Specifically, SICI is associated with a reduction in the number and amplitude of later 
I-waves, namely I2 and I3, with I-wave suppression remaining up to an ISI of 20 ms, 
the typical duration of the inhibitory postsynaptic potential mediated through GABAA 
receptors [59, 66].  In addition, GABAergic agonists acting via GABAA receptors 
appear to enhance I wave amplitudes and SICI [66-69].  Importantly, SICI and ICF 
appear to be physiologically distinct as indicated by a lower threshold for activation 
of SICI, and that SICI remains independent of the direction of current flow in the 
motor cortex, at least in healthy subjects, while ICF appears to be preferentially 
generated by current flowing in a posterior-anterior direction [61].    
 
Long interval intracortical inhibition (LICI) is elicited by delivering a suprathreshold 
conditioning stimulus 50-200ms prior to a suprathreshold test stimulus [70].  
Although both SICI and LICI produce MEP inhibition by reducing the late indirect (I) 
waves, there is evidence that SICI and LICI are mediated by different population of 
neuronal cells given that markedly different pattern of response is seen when test 
stimulus intensity is varied [71].  This is further supported by the fact that there is lack 
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of correlation between the extent of SICI and LICI in that instead of potentiating the 
SICI, LICI reduces or even reverses SICI, which has been postulated to be due to 
direct inhibition of the circuits mediating SICI as well as the output neurons [71].  
Lastly, SICI and LICI are mediated by different receptor subtypes, with LICI being 
mediated by GABAB receptors and SICI by GABAA receptors [54]. 
 
As with other TMS parameters, the changes in SICI have been varied and inconsistent 
in PD.  Specifically, while some studies have failed to document any significant 
changes [31, 72, 73], others have documented a significant reduction in SICI at rest, 
with at least partial normalisation with dopaminergic therapy and “ON-DBS” 
condition, matched by improvement in clinical motor scores as measured by the 
UPDRS [7, 11, 30, 32, 33, 74], suggesting that abnormalities in thalamo-cortical 
motor pathways may in part underlie the reduced SICI and thereby development of 
motor symptoms in PD.  However, there are also studies that showed significantly 
reduced SICI despite the fact that patients were on medication [32, 75] and others 
which showed no changes in SICI [5].  
 
It has been argued that the discordant SICI findings in PD patients may relate to 
methodological issues.  Specifically, MacKinnon and colleagues [5] reported that 
SICI was reduced only when the CSI was set to 90% or 100% of the RMT while 
stimulation with CSIs 40-80% RMT were normal.  Given that facilitatory circuits, i.e. 
short interval intracortical facilitation (SICF) may be activated at these higher 
conditioning stimulus intensities [63], it was postulated that abnormalities in SICI in 
PD were due to activation of the facilitatory pathways on the basis of reduced 
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threshold rather than abnormalities in the inhibitory pathways.  However, the 
possibility that the reduced SICI resulted from the summation of descending volleys 
from both the conditioning and test stimuli cannot be excluded because CSIs above 
AMT were used [5].  This was underscored by the finding that dopaminergic 
medications failed to significantly influence SICI (MacKinnon et al 2005).  Of further 
relevance, others have failed to establish a relationship between changes in SICI and 
clinical measures of motor impairment in PD [7, 47].   Recently, Ni et al. [76] 
provided further evidence that the reduced SICI may be due to enhanced facilitation 
rather than reduced inhibition.  They examined the time course of SICI and SICF, and 
demonstrated that SICF was enhanced in the medication “off” state and that this 
normalised with dopaminergic medications, supporting the hypothesis that reduced 
SICI in the OFF state may be due to increased SICF.  Of interest, they showed that 
there was a small reduction in SICI in the absence of significant SICF, which only 
partially normalised with dopaminergic medication.  Together, there appears to be 
both dopamine responsive facilitatory networks and non-dopaminergic GABAA 
pathways contributing to motor cortical dysfunction in PD [76, 77]. 
 
It is noteworthy that studies that have reported normal SICI have used higher test 
stimulation intensities above 120% RMT [11, 31].  Disease severity – Several studies 
that have reported significant reduction in SICI were in patients with relatively 
advanced disease [7, 74].  Studies that have examined de novo PD patients or those 
with mild to moderate disease reported equivocal changes in SICI, with some 
reporting normal [5, 11] while others reduced SICI [75, 78]. 
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Mixed findings have been reported in ICF.  Several groups have reported normal ICF 
in both ON and OFF-medication states, consistent with the notion that decreased SICI 
in PD is not mediated by changes in ICF [7, 30, 76], but others have reported 
significantly reduced ICF, consistent with abnormalities in facilitatory motor inputs 
and cortical connections in PD [78-80].  Reduced ICF has been demonstrated in both 
early and advanced PD patients [31, 78] (although it should be noted that these studies 
have been associated with variable changes in SICI).  Reduced ICF could be due to 
reduction of facilitatory inputs involved in ICF and could underlie the impaired 
muscle activation [81] as well as movement scaling deficit [82] that underlies 
bradykinesia in PD. 
 
LICI has been reported to be abnormal in PD, but there are mixed reports with 
increased as well as decreased intracortical inhibition at long ISIs (100-250ms) [45].  
The fact that there is reasonably good evidence for decreased cortical inhibition, with 
SICI being reduced and CSP shortened, makes determining the changes in LICI an 
important question in terms of understanding the cortical mechanisms in PD 
pathophysiology.  Reduced LICI would support the hypothesis that loss of 
dopaminergic transmission in PD patients is associated with impaired motor cortical 
inhibitory mechanisms [74], while increased LICI would support the hypothesis that 
there is differential modification of the motor cortex in PD [47].  Pierantozzi et al. 
[74] reported significantly reduced LICI, which was maximal at 80-100 ms and 
reversed with Apomorphine, but on the other hand, Beradelli et al. [48] reported 
increased LICI in the setting of shortened CSP [48], which has been reproduced by 
other groups, including one that used a similar protocol used by Beradelli et al. [47, 
83].  In addition, this would be consistent with the finding that SICI is reduced when 
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tested in the presence of LICI [71], suggesting that LICI can inhibit SICI through 
activation of presynaptic GABAB receptors. 
In summary, results from TMS studies in PD have been somewhat inconsistent, most 
likely owing to the methodological issues within and between studies.  Studies have 
employed varying stimulation intensities for conditioning and test stimuli and often 
study subjects were not carefully selected out according to disease severity, 
medication states and presence or absence of treatment related complications such as 
motor fluctuations and dyskinesia.   
Notwithstanding this, there is reasonably good evidence that SICI is reduced and CSP 
is shortened in PD and that these improve to an extent with dopaminergic therapy.  
These findings need to be confirmed in carefully selected patient groups and further 
research into the relationship between the changes in cortical excitability and clinical 
as well as objective measures of disease status will help to clarify the significance of 
cortical excitability changes in PD pathophysiology and whether modern TMS 
techniques might be of use in drug trials as an objective biomarker of disease severity. 
 
1.4 CONCEPTS OF PD PATHPOHYSIOLOGY 
Marsden proposed that the role of the basal ganglia in motor control is to facilitate 
desired movements and to inhibit unwanted movements [84, 85].  Likewise, the 
surround inhibition motor control model, proposes that basal ganglia is essential in 
inhibiting competing circuits so that the motor cortex can execute the optimal motor 
program [86].  This notion is supported by the TMS finding that in normal subjects, 
SICI is reduced in the agonist muscle prior to voluntary movement but not in the 
antagonist muscle, thereby focussing the excitatory drive to produce the intended 
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movement [87, 88].  Although it is uncertain whether the TMS changes in PD are 
primary or secondary or even effects of dopaminergic therapy, one could speculate 
that the finding of reduced SICI in PD would be consistent with the idea that the 
reduced intracortical inhibition in PD allows the “unhelpful” competing motor circuits 
to be active during an intended movement, interrupting the focus of neuronal activity 
onto the appropriate pathways thus leading to reduced movement speed and amplitude 
[56].  However, the recent evidence that reduced SICI arises from enhancement in the 
SICF subcomponent of SICI would be consistent with the notion that there is 
increased excitability of corticospinal neurons in PD patients [76, 89].  This could be 
a compensatory strategy against decreased excitatory input from the motor thalamus 
to the primary motor cortex arising from reduced excitatory activities in the direct 
pathway and increased activities in the indirect pathway, resulting from loss of 
dopaminergic neurons in the substantia nigra [90, 91]. 
In addition to the abnormalities in the inhibitory circuits, intracortical facilitation 
(ICF) has been reported to be significantly reduced in PD, indicating that various 
facilitatory motor inputs and cortical connections are also defective in PD [37, 78-80].  
It has been suggested that this might represent a compensatory response to excessive 
corticospinal motor output at rest, i.e. steeper SR curve [37].  However, it should be 
noted that the steeper SR curve itself has also been postulated as a compensatory 
mechanism against slow recruitment of commands to move by making it easier to 
recruit activity from a resting state [4].  
In summary, there still remain significant uncertainties about the role of cortical 
excitability changes in PD.  Perhaps this is best highlighted by the fact that similar 
cortical excitability changes have been reported in dystonia which is an example of 
    
16 
hyperkinetic movement disorder which gives rise to unwanted excessive movements 
rather than paucity of movements in PD.  Currently, it remains to be shown whether 
the changes seen in cortical excitability are primary, compensatory or secondary to 
effects of dopaminergic medications, but recent evidence from Ni et al. [76] raises the 
possibility that reduced SICI in PD and dystonia may be underpinned by opposite 
changes in the subcomponents of SICI.  In PD, SICI may be reduced due to increased 
facilitation (SICF) while in dystonia, it may be reduced due to increased inhibition in 
the subcomponents of SICI. 
 
One possible way to unravel the significance of cortical excitability changes in the PD 
pathophysiology would be to examine how changes in cortical excitability relate to 
clinical and objective measures of clinical features of PD, including bradykinesia and 
rigidity.  Another way would be to examine how changes in cortical excitability vary 
in different motor states.  For example, if intracortical inhibition is in fact important 
for correct specification and selection of movements, then its behaviour during task 
performance is likely to reveal how cortical excitability changes contribute to 
pathophysiology of PD [77].   
 
1.5 CONCLUSIONS 
Cortical excitability studies using paired-pulse TMS has been extensively applied in 
the field of movement disorders and significant abnormalities have been reported in 
various parameters.  However, the significance of the changes in cortical excitability 
remains incompletely understood, as its relationship with clinical and 
neurophysiological measures of impairment and disability has not been investigated in 
    
17 
detail.  One of the areas of interest is the question of how much of the reported 
findings are primary or instead compensatory as this can have potential implications 
for therapeutics.  Therefore further research is required to gain further insights into the 
reported cortical excitability changes in various disorders.  It is likely that with deeper 
understanding of the significance of cortical excitability changes in one disease will 
spark and translate into further research and insights into other related movement 
disorders and hence it would seem fitting to concentrate the research efforts on the 
prototypical basal ganglia disorder, namely PD. 
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Chapter 2 DYSFUNCTION OF CORTICAL AND 
SPINAL INHIBITORY CIRCUITS UNDERLIE 
DEVELOPMENT OF STIFF-MAN SYNDROME 
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Abstract 
Background: Stiff-man syndrome (SMS) is a rare autoimmune disorder characterised 
by fluctuating muscular rigidity and spasms. Dysfunction of GABA-ergic intracortical 
circuits has been reported in SMS and shown to correlate with anti-glutamic acid 
decarboxylase antibody (anti-GAD Ab) levels in the cerebrospinal fluid, although the 
role of this GABA-ergic dysfunction in the disease pathophysiology remains to be 
fully elucidated.  Consequently, the present study utilised novel threshold tracking 
transcranial magnetic stimulation techniques to further explore the pathophysiology of 
clinical features in SMS.  
Methods: Cortical excitability studies were undertaken in 5 SMS patients, using a 90 
mm circular coil, and results were compared to 61 normal controls. All patients were 
clinically staged for disease severity and assessed using exteroceptive reflexes and 
serum anti-GAD Ab levels.  
Results: Short interval intracortical inhibition (SMS, -1.2±2.4%; controls, 10.3±0.7%; 
P<0.001) and cortical silent period duration (SMS, 159.1±18.7 ms; controls, 
210.2±3.1 ms; P<0.001) were significantly reduced in SMS patients while 
intracortical facilitation was increased (SMS -6.3 ± 0.9%; controls -0.4±0.8; P<0.01).  
In contrast, exteroceptive reflexes were abnormal at presentation but absent in all but 
one patient at the time of this study. There was no correlation between either changes 
in cortical function or exteroceptive reflexes and clinical disease severity or serum 
anti-GAD Ab levels.  
Conclusions: There is dissociation between measures of cortical hyperexcitability, 
spinal hyperexcitability, clinical disease severity and anti-GAD Ab levels in SMS. 
This finding suggests complex mechanisms are likely to underlie the pathophysiology 
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of clinical features in SMS and have implications for treatment and disease 
monitoring.   
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2.1 INTRODUCTION 
Stiff-man syndrome (SMS) is an autoimmune disorder characterised by fluctuating 
muscular rigidity and spasms, most prominent in axial and proximal limb muscles 
usually in a symmetric manner [92].  Up to 60-80% of the patients harbour serum 
anti-glutamic acid decarboxylase (GAD) antibody, which have been shown to inhibit 
GABA synthesis in vitro [93].  Although dysfunction of intrinsic cortical inhibitory 
GABA-ergic circuits has been reported [94-96], the pathophysiological mechanisms 
underlying the development of clinical features of SMS remain to be fully elucidated.  
 
Cortical function, and in particular cortical excitability, may be assessed by using 
paired-pulse transcranial magnetic stimulation (TMS) techniques [26, 58]. Paired 
pulse TMS techniques utilising the constant stimulus method, have reported cortical 
hyperexcitability in SMS, thereby suggesting an impairment of GABA-ergic 
inhibitory cortical interneuronal circuits [94, 96]. Of further relevance, spinal reflex 
myoclonus in SMS has been reported as indicated by the presence of pathological 
exteroceptive reflexes, reportedly a biomarker of spinal hyperexcitability mediated by 
propriospinal pathways [92, 95, 97]. Unexpectedly, spinal motor neuronal excitability 
and the function of local spinal inhibitory circuits (GABA-ergic interneuron mediated 
reflexes) were reportedly normal [95, 98].  
 
Separately, cortical hyperexcitability has been shown to correlate with anti-GAD 
antibody levels in the cerebrospinal fluid (CSF) [96], thereby suggesting that anti-
GAD antibodies underlie the development of cortical hyperexcitability in SMS.  The 
role of cortical hyperexcitability in development of symptoms of SMS, however, 
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remains obscure [99]. In an attempt to further clarify the pathophysiology of clinical 
features of SMS, the present study utilised novel threshold tracking TMS techniques 
to assess: 
i. whether cortical GABA-ergic dysfunction was a feature of SMS; 
ii. the relationship between cortical hyperexcitability and a measure of spinal 
hyperexcitability – exteroceptive reflexes; 
iii. the relationship between either cortical or spinal hyperexcitability and clinical 
features of SMS. 
 
2.2 METHODS 
Studies were undertaken in 5 patients with SMS (1 male, 4 females, mean age 57.8 
years, age range 26-83) referred to the Movement Disorders Unit at Westmead 
Hospital, Sydney, Australia. The diagnosis of SMS was based on a typical 
presentation with back pain, stiffness and stimulus-induced spasm in 4/5 and stiff 
limb syndrome subsequently generalising in 1 patient, together with supportive 
investigations including positive exteroceptive reflexes at presentation and positive 
anti-GAD antibodies in all patients. At the time of testing, all patients exhibited stable 
disease and their therapy had not been changed for at least 3 months. Regular 
medications included benzodiazepines that were not discontinued for the study. All 
patients gave informed consent to the procedures, which were approved by the 
Sydney Western Area Health Service Human Research Ethics Committee. 
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2.2.1 Clinical disease severity 
All SMS patients were clinically staged using the distribution-of-stiffness and 
heightened sensitivity scales [100], and were based on reported symptoms in the 
preceding week. For heightened sensitivity, 1 point was given for the presence of 
noise-induced stiffness and cramps, visual stimuli-induced stiffness and cramps, 
somatosensory-induced stiffness and cramps, voluntary activity induced spasms, 
emotional upset and “stress”-induced spasms, awakenings due to nocturnal spasms, 
and untriggered cramps and spasms (maximum score, 7). For distribution of stiffness, 
1 point was given for the presence of stiffness in each of the following areas: face, 
arms, upper trunk, abdomen, lower trunk, and legs (maximum score, 6). 
 
2.2.2 Cortical excitability 
Cortical excitability studies were undertaken by applying a 90 mm circular coil to the 
motor cortex with currents generated by two high-power magnetic stimulators 
connected via a BiStim (Magstim Co., Whitland, South West Wales, UK).  
Conditioning and test stimuli could be independently set and delivered through one 
coil.  Paired-pulse threshold tracking TMS was undertaken according to a previously 
reported technique [26]. Briefly, the motor evoked potential (MEP) amplitude was 
fixed and changes in the test stimulus intensity required to generate a target response 
of 0.2 mV (± 20%), when preceded by sub-threshold conditioning stimuli, were 
measured [26]. The MEP response was recorded over the right abductor pollicis 
brevis (APB).  Resting motor threshold (RMT) was defined as the stimulus intensity 
required to maintain this target MEP response. Initially, the maximum MEP 
amplitude (mV), MEP onset latency (ms) and cortical silent period (CSP) duration 
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were recorded with magnetic stimulus intensity set to 140% RMT.  Three stimuli 
were delivered at this level of stimulus intensity.  Central motor conduction time 
(CMCT, ms) was calculated according to the F-wave method [101].  
 
Short interval intracortical inhibition (SICI) and intracortical facilitation (ICF) were 
measured according to a previously devised protocol [26] . SICI was determined by 
using sub-threshold conditioning stimuli (70% RMT) at increasing interstimulus 
intervals (ISIs) as follows: 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 7 ms. ICF was measured at 
ISIs of 10, 15, 20, 25 and 30 ms. Stimuli were delivered sequentially as a series of 
three channels: channel 1 tracked the stimulus intensity required to produce the 
unconditioned test response (i.e., RMT); channel 2 monitored the response to the 
subthreshold conditioning stimulus; and channel 3 tracked the stimulus required to 
produce the target MEP when conditioned by a stimulus equal in intensity to that on 
channel 2.  Stimuli were delivered every 5-10 seconds (stimulus delivery was limited 
by the charging capability of the BiStim system) and the computer advanced to the 
next ISI only when tracking was stable.   
 
SICI was measured as the increase in the test stimulus intensity required to evoke the 
target MEP.  Inhibition was calculated off-line as follows [26]:  
Inhibition = (Conditioned test stimulus intensity – RMT)/RMT * 100 
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2.2.3 Spinal excitability 
In order to assess spinal excitability, we measured exteroceptive reflexes following 
median nerve stimulation at the wrist, using a modified technique of Meinck and 
colleagues [95].  Spinal hyperexcitability is reflected by the presence of spinal reflex 
myoclonus. Briefly, a train of 6 square wave pulses of 0.5ms duration were delivered 
at 200Hz to the median nerve at the wrist just proximal to the wrist crease. The 
stimulus intensity was adjusted to 1.5-2.0 times the motor threshold as detected by 
muscle twitch. Stimulation was repeated 5-6 times, and each stimulation was 
delivered at greater than 45-second intervals to avoid habituation. Surface 
electromyographic (EMG) recordings were obtained over the sternocleidomastoid, 
paraspinals at C7, T4, T12, L4, and rectus femoris muscles using Ag-AgCl electrodes 
placed 2 cm apart. Recorded EMG activity was rectified and the area under the curve 
for all reflex EMG activity between 50 and 800 ms after the stimulus was calculated. 
The latency (ms) to onset was also measured. 
 
2.2.4 Peripheral studies 
In the same sitting, the median nerve was stimulated electrically at the wrist using 5-
mm Ag-AgCl surface electrodes (ConMed, Utica, USA).  The resultant compound 
muscle action potential (CMAP) response was recorded from the APB and the CMAP 
onset latency and peak-peak amplitude were measured.   
 
Recordings of MEP and CMAP responses were amplified and filtered (3Hz-3kHz) 
using a Grass ICP511 A.C. amplifier and sampled at 10 kHz using a 16-bit data 
acquisition card (National Instruments, Austin, Texas; PCI-MIO-16E-4). Data 
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acquisition and stimulation delivery (both electric and magnetic) were controlled by 
QTRAC software (copyright Institute of Neurology, Queen Square, London, UK). 
 
2.2.5 Anti-GAD antibody titre 
Anti-GAD antibody levels were measured at the same visit. For detection and 
quantification of anti-GAD antibodies in serum, GAD65 antibody ELISA kit (RSR 
Ltd, Cardiff, UK) was used. The results are reported in manufacturer’s units per 
millilitre (normal <10 U/mL). The final concentration of antibodies was obtained after 
normalisation of the different dilutions to the RSR standard curve in the kit assay.  
 
2.2.6 Statistics 
Cortical excitability in SMS patients was compared to 61 healthy controls (31 males, 
30 females, mean age 45.8 years, age range 23-83).  Student t-test test was used to 
compare mean differences between SMS patients and controls. Correlations between 
excitability indices and clinical scales were analysed by Pearson’s rank test.  A 
probability (P) value of < 0.05 was considered statistically significant. Results are 
expressed as mean ± standard error of the mean. 
 
2.3 RESULTS 
2.3.1 Clinical disease severity 
The clinical and laboratory characteristics of the 5 SMS patients are outlined in Table 
2-1. The mean disease severity score, combining distribution-of-stiffness and 
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heightened sensitivity scales, was 5.8 (range: 0-12) indicating a mild-to-moderate 
level of disease activity. All patients tested positive for anti-GAD antibodies, with the 
mean anti-GAD antibody titre being 1, 248,974 U/mL (range: 7,020 - 4,621,000).   
 
 
Table 2-1  Clinical characteristics of patients.  Disease duration refers to the period from 
symptom onset to date of testing.  Disease severity was determined by adding the scores from 
distribution of stiffness (maximum score, 6) and heightened sensitivity (maximum score, 7) scales 
(see Methods).  Serum anti-GAD antibody levels (normal <10 U/ml) were measured at the time of 
cortical excitability studies.  Total daily dose of medications was assessed in each patient. 
 
 
2.3.2 Spinal excitability 
Exteroceptive reflexes were positive with evidence of spinal reflex myoclonus in all 
patients at the time of diagnosis, indicating spinal hyperexcitability (Figure 2-1). 
However, at the time of assessment of cortical excitability in the present study, 
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enhanced exteroceptive reflexes were present in only 1 patient, with a latency of 56 
ms. 
 
2.3.3 Cortical excitability 
Short interval intracortical inhibition represents an increase in the conditioned 
stimulus intensity required to track a constant target MEP of 0.2 mV, and typically 
develops between interstimulus intervals of 1-7 ms with two peaks evident, a smaller 
peak at ISI 1ms and larger peak at 2.5-3 ms [26].  SICI is thought to be mediated by 
GABAA-ergic activity [58, 63, 67, 102, 103]. The average SICI, between ISIs of 1-7 
ms, was significantly reduced in SMS patients when compared to controls (SMS 
averaged SICI -1.2 ± 2.4%; controls 10.3 ± 0.70%, P< 0.001, Figure 2-2).  In addition, 
peak SICI at ISI 1ms (SMS 1.6 ± 1.7%; controls 7.4 ± 0.8%; P < 0.05, Figure 2-3A) 
and ISI 2.5-3ms (SMS 2.1 ± 2.9; controls 15.3 ± 1.3; P < 0.01, Figure 2-3B) were also 
reduced in SMS patients. 
 
Following SICI, a period of facilitation develops between ISIs of 10-30 ms and is 
reflected by a decrease in the conditioned test stimulus intensity required to evoke a 
target MEP.  Intracortical facilitation is believed to be mediated by glutamate activity 
[26, 104].  ICF was significantly increased in SMS patients when compared to 
controls over ISIs 10-30 ms (SMS -6.3 ± 0.9%; controls -0.4±0.8; P<0.01, Figure 2-
3C).   
 
Cortical silent period refers to a period of electrical silence in a contracting muscle, 
and was measured from the onset of the MEP to the return of EMG activity [26, 49].  
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CSP is believed to be mediated by GABA-ergic activity acting via GABAB receptors 
[50, 52].  The cortical silent period duration was significantly reduced in SMS 
patients when compared to controls (SMS 159.1±18.7 ms; controls 210.1 ±3.1 
P<0.001, Figure 2-3D) 
 
In contrast to significant differences in cortical GABA-ergic function, the resting 
motor threshold (SMS 56.9 ± 4.9%; controls 59.5 ± 1.0%) and MEP amplitude (SMS 
17.2 ± 3.9%; controls 24.9 ± 1.8%) were similar between the groups, as was the 
central motor conduction time (SMS 5.41 ± 0.36 ms; controls 5.29 ± 0.21 ms).   
 
2.3.4 Peripheral studies 
The CMAP amplitude (SMS 12.3 ± 2.1 mV; controls 10.2 ± 0.4 mV) and 
neurophysiological index (SMS 2.8 ± 0.7; controls 2.5 ± 0.1) were similar in SMS 
patients and controls, excluding peripheral abnormalities as the basis of abnormalities 
demonstrated in cortical excitability.  
 
2.3.5 Relationship between clinical, immunological, and neurophysiological 
findings 
There was no significant correlation between SICI and the heightened sensitivity (R= 
0.31, P = 0.61) or distribution of stiffness (R = 0.31, P = 0.62).  There was no 
significant correlation between SICI (R = 0.22, P = 0.99), ICF (R = -0.5, P = 0.39) or 
CSP (R = -0.154, P = 0.80) and serum anti-GAD antibody levels. Assessment of CSF 
anti-GAD antibodies was not undertaken in this study.   
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Figure 2-1  A representative exteroceptive reflexes in a patient at the time of diagnosis. Note the 
onset of pathological EMG activity at a latency of 55 ms, seen first in T12 paraspinal muscles and 
followed by ordered recruitment of rostral (T4 and C7) and caudal L4 paraspinal muscles, as 
well as recruitment of the quadriceps femoris (QF) and sternocleidomastoid (SCM) muscles. 
 
 
 
 
 
 
Figure 2-2  Short interval intracortical inhibition (SICI), was markedly reduced in stiff-man 
syndrome (SMS) patients when compared to normal controls (P<0.001). 
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Figure 2-3  There was a significant reduction of SICI in stiff-man syndrome (SMS) patients at 
both (A) ISI of 1 ms and (B) ISI of 2.5-3ms; * P < 0.05; **P < 0.01.  (C) Intracortical facilitation 
(ICF) was significantly increased in SMS patients when compared to controls over ISIs 10-30 ms; 
**P < 0.01.  (D) Cortical silent period (CSP) duration was significantly reduced SMS patients; 
***P<0.001. 
 
 
2.4 DISCUSSION 
This is the first study to concurrently assess cortical and spinal neurophysiology, anti-
GAD antibodies and clinical features in a cohort of stiff-man syndrome patients.  The 
present study has identified evidence of ongoing cortical GABA-ergic dysfunction in 
a cohort of chronic stiff-man syndrome patients treated with high doses of 
benzodiazepines.  Specifically, there was a significant reduction in short interval 
intracortical inhibition and cortical silent period duration with an increase in 
intracortical facilitation. It is noteworthy that these changes in cortical function 
persisted despite a relative improvement in spinal hyperexcitability as well as partial 
symptomatic benefit during treatment with high doses of benzodiazepines.  However, 
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the most notable finding is that there was a dissociation between cortical GABA-ergic 
dysfunction, spinal hyperexcitability, clinical disease severity and anti-glutamic acid 
decarboxylase antibody levels.  Taken together, these findings suggest that although 
there is dysfunction of GABA-ergic intracortical circuits, there are complex 
interrelationships between these factors in the generation of the clinical features of 
SMS. 
 
2.4.1 Pathophysiology of cortical dysfunction in SMS 
It is now accepted that SICI is mediated by cortical inhibitory neurons acting via 
GABAA receptors [58, 63, 102, 103, 105]. Evidence for such a mechanism is provided 
by pharmacological studies revealing that GABA agonists, such as benzodiazepines, 
enhance SICI [104].  Of further relevance, ICF also appears to be modulated by 
GABA-ergic processes acting via GABAA receptors, with ICF being reduced by 
GABAA receptor agonists [23, 42, 104].  As such, the finding of persistent reduced 
SICI and increased ICF in the present cohort of SMS patients, despite benzodiazepine 
treatment, suggest significant dysfunction of GABA-ergic inhibitory neurons acting 
via GABAA receptors and is in keeping with previous studies [94, 106]. 
 
In addition to dysfunction of GABAA circuits, the findings in the present study 
suggest concomitant dysfunction of GABAB circuits.  Specifically, the cortical silent 
period is mediated by cortical inhibitory mechanisms acting via GABAB circuits and 
local spinal inhibitory processes [50, 52].  Given that CSP duration was significantly 
reduced in SMS patients, dysfunction of cortical GABA-ergic processes acting via 
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GABAB receptors may in part account for this finding, although a contribution from 
dysfunctional spinal inhibitory processes cannot be discounted [50, 52]. 
   
2.4.2 Relationship between cortical dysfunction and ant-GAD antibodies 
Only one previous study has examined the relationship between cortical excitability 
and anti-GAD antibodies [96]. Our study supports their finding of a lack of 
correlation between serum anti-GAD antibody levels and measures of cortical GABA-
ergic dysfunction.  In their study, a correlation was found between cortical excitability 
and CSF anti-GAD antibody levels, which were not assessed in the present study.  
The lack of a correlation between cortical excitability and serum anti-GAD levels is in 
keeping with previous reports that serum anti-GAD antibody levels do not reflect CSF 
levels, due to strong intrathecal production of anti-GAD antibodies by a clonal 
activation of B cells within the central nervous system in SMS patients [107]. 
 
2.4.3 What underlies the generation of symptoms in SMS? 
A reduction of GABA synthesis, mediated by anti-GAD antibodies, has been 
postulated as a likely mechanism underlying the development of clinical features of 
SMS, including axial and limb rigidity, muscle stiffness and stimulus-induced spasms 
[92, 93, 107].  Specifically, it was postulated that inhibition of GABA synthesis 
would result in a reduction or loss of supraspinal inhibition, thereby resulting in 
hyperexcitability of local spinal circuits and ultimately the clinical features of SMS 
[92, 95]. 
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Our findings suggest that there may not be a simple causal relationship between 
cortical GABA-ergic dysfunction and spinal hyperexcitability and associated 
stimulus-induced muscle spasms in SMS.  The absence of a correlation between TMS 
biomarkers of cortical GABA-ergic dysfunction and measures of stimulus induced 
spasms, such as heightened sensitivity, would seem to argue against a significant 
contribution of cortical GABA-ergic dysfunction to the development of stimulus-
induced muscle spasms.  Of further relevance, the absence of correlation between 
measures of cortical GABA-ergic dysfunction and spinal hyperexcitability, as 
reflected by exteroceptive reflexes, suggests that cortical mediated disinhibition of 
spinal reflexes may not be the predominant mechanism underlying the development 
of clinical features in SMS [108].  Disinhibition of brainstem circuits directly 
mediating muscle tone and spasms, along with dysfunction of non-GABA-ergic 
inhibitory subcortical circuits may potentially contribute to local spinal 
hyperexcitability, and thereby symptom generation in SMS [97, 109].  From a 
therapeutic perspective, the findings in the present study may explain the limited 
efficacy of therapeutic measures aimed at solely modulating GABA-ergic circuits, 
highlighting the importance of considering novel therapeutic approaches in SMS. 
 
2.4.4 Limitations of the present study 
It could be argued that the findings in the present study were confounded by 
benzodiazepine therapy, an agent that modulates cortical processes [23].  This seems 
unlikely given that SICI and CSP were reduced, or moved in an opposite direction to 
that expected with exposure to benzodiazepines [23].  The  withdrawal or reduction in 
benzodiazepine dose for the purposes of this study would have been unethical in the 
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present SMS patients given the potential to lead to a marked exacerbation of 
symptoms, potentially resulting in death [110].  
 
2.5 CONCLUSIONS 
There is dissociation between measures of cortical hyperexcitability, spinal 
hyperexcitability, serum anti-GAD antibodies and clinical symptoms in stiff man 
syndrome. Spinal hyperexcitability and muscle stiffness and spasms are unlikely to be 
simply due to cortical disinhibition of spinal circuits.  This study highlights the 
current incomplete understanding of the pathophysiology of SMS.  More detailed 
studies of the relationship between cortical excitability and other features of SMS 
such as associated psychiatric symptoms, as well as studies of the relationship 
between brainstem excitability and features of SMS, may give further insights into the 
pathophysiology and treatment of SMS. 
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Chapter 3 Hand dominance influences side-to-side 
differences in tapping speeds but not SICI in 
normal subjects 
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ABSTRACT 
Background: Cortical processes underlying hand dominance has yet to be fully 
clarified.  There is good evidence that the degree of interhemispheric asymmetry in 
the size of the cortical hand area correlates highly with the asymmetry in hand 
performance in normal subjects.  However, results from cortical excitability studies 
using paired-pulse transcranial magnetic stimulation (TMS) have been inconsistent, 
with a lack of studies which have examined hand dominance objectively and 
correlated it against cortical excitability. 
Objectives: To explore the relationship between hand dominance and side-to-side 
differences in speed of ballistic hand movements and cortical excitability using the 
threshold tracking paired-pulse TMS. 
Methods:  Cortical excitability studies were undertaken in 10 normal subjects.  Short 
interval intracortical inhibition (SICI) was assessed using a threshold tracking paired-
pulse TMS with conditioning stimulus intensity set to 70% of resting motor threshold.  
Motor evoked potentials were recorded over the abductor pollicis brevis.  Hand 
tapping rate was measured for each side with a timed tapping task in which two 
electronic touch pads positioned 20 cm apart were tapped as fast as possible for 60 
seconds.  Data were grouped by hand dominance and comparisons were made 
between the dominant and non-dominant sides.  Interhemispheric differences in SICI 
were correlated with side-to-side differences in timed tapping task. 
Results:  There was a significant difference in the TR between the dominant and non-
dominant sides (mean difference = 28.2 ± 6.4, P < 0.01) but no significant 
interhemispheric difference in SICI (mean difference = -1.5 ± 2.5%, P = 0.57).  
Furthermore, there was no significant correlation between the interhemispheric 
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difference in SICI and the side-to-side difference in hand tapping rate (Spearman 
correlation coefficient = -0.25, P > 0.24). 
Conclusion:  The present study has identified that there is no significant asymmetry 
in cortical excitability between the dominant and non dominant cerebral hemispheres 
in normal subjects despite there being a clear asymmetry in motor performance as 
tested with an objective hand tapping task.  Furthermore, there was no correlation 
between the asymmetries in motor performance and cortical excitability, suggesting 
that hand dominance influences side-to-side differences in tapping speeds but not 
SICI in normal subjects. 
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3.1 INTRODUCTION 
Cortical processes underlying hand dominance has yet to be fully clarified.  There is 
consistent evidence that the degree of side-to-side asymmetry in the size of the hand 
area in the primary motor cortex correlates highly with the asymmetry in hand motor 
performance, i.e., handed dominance [111-113].  However, results from cortical 
excitability studies in normal subjects, comparing the dominant and non-dominant 
cerebral hemispheres have been inconsistent.   
A number of studies have reported significant functional differences in intracortical 
inhibition and facilitation between the dominant and non-dominant hemispheres 
within individual subjects [114-117], and additionally, significant differences in 
cortical excitability between the right handed and left handed subjects have been 
reported by a number of studies [113].  Specifically, Hammond et al. [114] reported 
that short interval intracortical inhibition (SICI) and intracortical facilitation (ICF) 
developed more rapidly with increasing conditioning stimulus intensity in the 
dominant hemisphere compared with non dominant hemisphere which was interpreted 
as the intracortical circuits being more “potent” in the dominant hemisphere, and 
hypothesised that this difference in shaping motor outflow contributes to the 
asymmetrical dexterity while Civardi et al [117] reported enhanced ICF and to a 
lesser extent SICI in the dominant hemisphere compared with non-dominant 
hemisphere in the right handed subjects although the left handed group did not show 
such hemispheric asymmetries.  However, other studies have reported minimal 
interhemispheric asymmetry in SICI and ICF [118, 119]. 
Motor threshold has been reported to be lower on the dominant hemisphere compared 
with the non-dominant hemisphere by a number of groups [19, 28, 120], but it has 
also been reported as being comparable between the dominant and non-dominant 
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sides and been replicated with slightly different techniques [117, 121, 122].  Further, 
cortical silent period has been reported to be shorter in the dominant hand compared 
with the non-dominant hand of right-handers [117, 122], but Cicinelli et al. reported 
no significant differences in cortical silent period. 
 
Significantly, almost all of the studies to date have determined the hand dominance 
based on preferred writing hand or handedness inventories, e.g. Oldfield inventory or 
Edinburgh Handedness Inventory, and only a few studies have measured the hand 
function objectively and correlated these with measures of cortical function [27, 111].   
Of note, the previous studies examining intracortical facilitation and inhibition have 
utilized the conventional paired-pulse TMS, which fixes the test stimulus and 
measures the changes in MEP when the test stimulation is preceded by a subthreshold 
conditioning stimulus.  One of the main limitations of this technique is marked 
variability in MEP amplitude with consecutive stimuli, making it is difficult to discern 
whether changes in the MEP produced are secondary to a true change in cortical 
excitability or, alternatively, represent fluctuations related to the delivery of the test 
stimuli [59, 62].  By setting a tracking target of 0.2 mV, located in a steep portion of 
the nonlinear SR curve [41], marked variability in MEP amplitudes translate to 
smaller changes in stimulus intensity, potentially overcoming this limitation and 
provides the added advantage of speeding up the recording process thereby allowing 
multiple recordings to be made in quick succession. 
In the present study, cortical excitability was measured from both cerebral 
hemispheres in 10 normal subjects using the threshold tracking paired-pulse 
transcranial magnetic stimulation (TMS) to examine whether there are significant 
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functional differences between the dominant and non-dominant hemispheres.  
Furthermore, hand motor performance was correlated with measures of cortical 
excitability.   
 
3.2 METHODS 
3.2.1 Subjects 
Studies were undertaken in 10 normal subjects (5males and 5 females, median age 65 
years, age range 46-72).  All subjects underwent review of their medical history 
including medications followed by detailed neurological examination and cleared of 
any neurological problems (See Table 1).   
All patients gave written informed consent to the research, which was approved by the 
Sydney Western Area Health District Human Research Ethics Committee. 
 
3.2.2  Handedness  
Handedness was rated using the Edinburgh Handedness Inventory and a score was 
calculated as a continuous variable for each patient from a scale ranging from -100 
and 100.  A score of 0 indicated ambidexterity while -100 denoted complete left 
handedness and 100, complete right handedness. 
 
3.2.3 Objective measures 
Tapping task  
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Speed of hand tapping was measured for each side with a timed tapping task in which 
subjects alternately tapped two electronic touch pads positioned 20 cm apart as fast as 
possible for 60 seconds as previously described [123]. The number of taps and 
changes in the rate of tapping between the first and the last 15-second epochs were 
measured for each hand.  
 
Cortical excitability 
Cortical excitability was assessed by measuring the resting motor threshold (RMT), 
short interval intracortical inhibition (SICI), intracortical facilitation (ICF) and 
cortical silent period (CSP) as previously described [26]. Briefly, paired-pulse 
threshold tracking TMS was undertaken by applying a 90 mm circular coil to the 
motor cortex with currents generated by two high-powered magnetic stimulators 
connected via a BiStim (Magstim Co., Whitland, South West Wales, UK) [26].  The 
MEP response was recorded over the right abductor pollicis brevis (APB).  RMT was 
defined as the stimulus intensity required to maintain the target MEP response of 0.2 
mV.  Cortical excitability was determined by fixing the motor evoked potential 
(MEP) amplitude at 0.2 mV (± 20%) (target response) and measuring the changes in 
the test stimulus intensity required to generate this target response, when preceded by 
a sub-threshold conditioning stimuli at various interstimulus intervals (ISIs) [26].  
Sub-threshold conditioning stimuli was set at 70% RMT.  SICI was measured at 
increasing ISIs as follows: 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 7 ms, and ICF at ISIs of 10, 
15, 20, 25 and 30 ms.  
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short interval intracortical inhibition was measured as the increase in the test stimulus 
intensity required to evoke the target MEP, and calculated off-line [26].  Intracortical 
facilitation was measured as the decrease in the conditioned test stimulus intensity 
required to evoke a target MEP. 
 
Cortical silent period refers to a period of electrical silence in a contracting muscle, 
and was measured from the onset of the MEP to the return of EMG activity with 
magnetic stimulus intensity set to 140% RMT [26, 49].  
3.2.4 STATISTICS 
Analysis of variance (ANOVA) was used to compare mean differences between the 
dominant hand and non dominant hand.  Correlations between excitability indices and 
objective motor performance (hand tapping rate) was analysed by Spearman’s rank 
test.  A probability (P) value of < 0.05 was considered statistically significant.  
Results are expressed as mean ± standard error of the mean. 
 
3.3 RESULTS 
Participant demographics are presented in Table 3-1.  
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Table 3-1  Subject demographics 
 
3.3.1 Cortical Excitability 
Motor Threshold 
RMT was comparable between the dominant and non-dominant sides (dominant = 
58.69 ± 3.0%; non dominant = 59.23 ± 2.9%). 
Motor evoked potential amplitude 
MEP amplitude was comparable (dominant = 2.29 ± 0.76; non-dominant = 2.36 ± 
0.60) as was MEP latency (dominant = 23.27 ± 0.49; non-dominant = 23.28 ± 0.48). 
Cortical silent period 
The CSP duration was also comparable between the DH and NDH (dominant = 223.4 
± 10.14; non-dominant = 227.1 ± 9.55; P = 0.80, Figure 3-1). 
 
Paired stimulation 
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Figure 3-1  CSP duration between the dominant and non dominant hemispheres. 
 
 
Figure 3-2  SICI between the dominant and non dominant hemispheres. 
 
 
 
Averaged SICI from ISIs of 1-7ms was 6.35 ± 2.1% on the dominant hand and 7.84 ± 
1.8% on the non dominant hand (Figure 3-2).  These were somewhat lower when 
compared with our normative data in 61 patients obtained from the right hand (10.3 ± 
0.7%).  ICF was -1.87 ± 1.2% on the dominant hand and -2.07 ± 2.74% on the non 
dominant hand compared with -0.4 ± 0.8 from our normative data.  CSP was 223.4 ± 
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10.1ms on the dominant hand while it was 227.1 ± 9.6ms on the non dominant hand, 
compared with 210.2 ± 3.1ms from our normative data. 
 
3.3.2 Objective hand function 
Timed tapping task 
There was a significant difference in tapping rate between the dominant and non-
dominant hands (dominant side 254.5 ± 6.7/minute; non-dominant side 226.3 ± 5.3 (P 
= 0.006). 
Relationship between cortical excitability studies and objective hand function 
There was no correlation between cortical excitability parameters and hand function 
as measured by hand tapping speed or EHI.  Given there was significant variability in 
the cortical excitability parameters between individuals, the side-to-side difference in 
SICI and ICF were correlated with side-side difference in hand tapping speed.  
However, the degree of asymmetry in TR between the dominant and non-dominant 
hands did not correlate with the degree of asymmetry in measures of cortical 
excitability, i.e., SICI, ICF and CSP. 
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Figure 3-3  Tapping speed between the dominant and non dominant hands. 
 
 
 
 
3.4 DISCUSSION 
To our knowledge, the present study is the first to apply threshold tracking paired-
pulse TMS to compare the cortical excitability between the two hemispheres in 
normal subjects.  The present study has identified that there is no significant 
asymmetry in cortical excitability between the dominant and non-dominant 
hemispheres in normal subjects despite the clear side-to-side difference in motor 
performance as measured with an objective hand-tapping task.  SICI and ICF were 
comparable between the two hemispheres, suggesting absence of asymmetry in 
GABAergic function as both SICI and ICF are mediated by cortical inhibitory 
neurons acting via GABAA receptors.  
Of interest, a number of studies have examined the cortical excitability of both 
cerebral hemispheres with TMS but the results have been inconsistent.  The results 
from the present study are in line with previous studies that have reported no 
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functional asymmetry between the motor cortices and suggest the presence of other 
influences such as ipsilateral cortical activation and transcallosal inhibition underlying 
hand dominance.  The fact that this finding has been replicated with two different but 
validated TMS techniques lends further support for the validity of the findings from 
the present study. 
The functional differences of the cerebral hemispheres in man can be explained with 
using two models.  One model hypothesises that hand dominance is a consequence of 
“intrinsic specialisation” such as asymmetry in the size of the motor cortex and motor 
threshold between the dominant and non-dominant motor cortices [111].  The other 
model assumes that both motor cortices have identical intrinsic function and the 
asymmetry hand dominance results from asymmetry in inhibitory interaction between 
the two motor cortices such as transcallosal inhibition or asymmetry of ipsilateral 
motor cortex activation [124].  It is noteworthy that a number of studies have 
examined the cortical excitability of both cerebral hemispheres with TMS but again 
the results have been inconsistent.  The results from the present study provide further 
evidence that rather than there being “intrinsic specialisation,” influences such as 
ipsilateral cortical activation and transcallosal inhibition likely underlie hand 
dominance.   
In conclusion, this study provides evidence that cortical excitability is symmetrical in 
healthy normal controls and as such hand dominance influences side-to-side 
difference in tapping speed but not SICI.  
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Chapter 4 Interhemispheric differences in cortical 
excitability in Parkinson’s disease 
    
50 
ABSTRACT 
Objective: To investigate whether there are interhemispheric differences in cortical 
excitability in Parkinson’s disease (PD), and whether these correlate with clinical and 
objective measures of bradykinesia and rigidity. 
Background: The pathophysiological mechanisms linking the dopaminergic deficits 
and motor manifestations are not well understood. Transcranial magnetic stimulation 
techniques have suggested abnormalities of cortical excitability in PD, but it remains 
unclear as to whether these abnormalities are a focal phenomena reflecting the 
asymmetrical motor and nigrostriatal deficit, or a generalised process. 
Methods: Cortical excitability studies were undertaken using threshold tracking 
paired-pulse TMS on the more and less affected sides in 12 PD subjects in the OFF-
medication state and compared with 10 age-matched control subjects as previously 
described.  The results were correlated with clinical as well as objective measures of 
bradykinesia and rigidity by also assessing MDS-UPDRS, timed hand tapping task 
and angular impulse score using a torque motor.   Results were compared between 
more and less affected hemispheres in PD subjects and between dominant and non-
dominant hemispheres and to normal controls.  
Results: ICF was statistically significantly reduced in the PD subjects compared with 
the age matched control subjects (F(41) = 3.678, *P=0.02), but there were no 
significant side-to-side differences between the more and less affected sides.  
However, there were significant interhemispheric differences in SICI (mean 
difference -4.06 ± 1.72 %, P < 0.04) and CSP (mean difference -12.8 ± 4.5 ms, P < 
0.02) although both SICI and CSP were not significantly different to controls.  There 
was a significant correlation between interhemispheric differences in SICI and side-
to-side differences in both clinical (ρ = -0.59, P < 0.05) and objective measures (ρ = -
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0.80, P < 0.002) of bradykinesia, while there was no such correlation in normal 
controls. 
Conclusion: The results suggest that cortical dysfunction is an asymmetrical process 
in PD, reflecting the asymmetry in motor and nigrostriatal deficit.  Furthermore, the 
significant correlation between interhemispheric differences in SICI and side-side 
differences in akinesia suggest that asymmetry in cortical excitability is a 
pathophysiological feature of PD and contribute to asymmetrical motor impairment, 
although it remains unclear to what extent these changes are primary or 
compensatory. 
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4.1 INTRODUCTION 
Parkinson’s disease (PD) is characterized by progressive asymmetric loss of 
dopaminergic neurons in the nigrostriatal pathways with corresponding asymmetric 
bradykinesia, rigidity and tremor.  However, the pathophysiological mechanisms 
linking the dopaminergic deficit and motor impairments are poorly understood.   
The motor cortex is the primary target for the output neurons of the basal ganglia, and 
therefore the deficits in movement control that occur in the basal ganglia as part of PD 
should ultimately be reflected in the activity of the cortical neurons.  Indeed, 
transcranial magnetic stimulation (TMS) techniques have revealed relatively 
consistent abnormalities of cortical excitability in PD as indicated by reduction in 
short interval intracortical inhibition (SICI) and cortical silent period (CSP), which 
normalise with dopaminergic treatment and deep brain stimulation, suggesting a role 
for cortical dysfunction in disease pathophysiology.  However, the significance of 
these findings remains uncertain, as a relationship has yet to be demonstrated between 
the cortical excitability changes and impairments in motor function.  It has already 
been shown that the changes in cortical excitability do not arise simply because of 
abnormal muscle tone, i.e. rigidity that characterises PD as demonstrated by normal 
motor thresholds (MTs) and magnetic evoked potentials (MEPs) [5, 7, 30-33] and 
therefore if cortical excitability changes can be shown to be a focal phenomenon, this 
would provide a further link between the asymmetrical nigrostriatal pathology and 
corresponding clinical manifestations and support the role of cortical excitability 
changes in the disease pathophysiology.   
There have been a small number of studies, which examined the interhemispheric 
differences in cortical excitability in PD patients [6, 28, 78] but the findings have been 
inconsistent.  A single-pulse TMS study reported significantly reduced MT and 
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shortened CSP duration on the more affected hemisphere [28] but another study 
reported no significant side-to-side differences in MEP and CSP [6] although this 
study showed significant correlation between maximal CSP duration and Unified 
Parkinson’s Disease Rating Scale (UPDRS) scores on the more affected side as well 
as correlation between some less well validated parameters (MEP-Int50 and CSP-
Int50) and UPDRS on the less affected side. This finding may suggest evolution of 
TMS parameters from a less to more symptomatic state [6].  Further, a paired-pulse 
TMS study using the constant stimulus technique in PD subjects with early disease 
reported no significant side-to-side differences in SICI and ICF between the more and 
less affected hemispheres although this study found significant reduction in SICI and 
ICF [78]. 
Before cortical excitability changes can be reliably interpreted in PD, the influence of 
hand dominance on cortical excitability needs to be clarified as results from cortical 
excitability studies comparing the dominant and non-dominant cerebral hemispheres 
in normal subjects have been inconsistent.  A number of studies have reported 
significant differences in SICI and ICF between the dominant and non-dominant 
hemispheres of individual subjects [114-117] and similarly, significant differences in 
cortical excitability have been reported between the right handed and left handed 
subjects [113].  However, others have reported conflicting findings with minimal 
interhemispheric asymmetry in SICI and ICF [118, 119, 121, 125] although it has to 
be noted that the influence of handedness was only assessed in one of these studies in 
which all of the subjects were right handed [121]. 
Of note, these previous studies have utilized the conventional paired pulse TMS, 
which fixes the test stimulus and measures the changes in MEP when the test 
stimulation is preceded by a subthreshold conditioning stimulus.  One of the main 
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limitations of this technique is the marked variability in MEP amplitude with 
consecutive stimuli such that multiple stimuli need to be delivered at each 
interstimulus interval, which likely makes the technique less reliable in PD as the 
patients may change from one state to another in the time required to complete a 
study, particularly in those with motor fluctuations.   
The present study assessed the cortical excitability of the more-affected versus less-
affected cerebral hemispheres in 12 PD subjects using the threshold tracking paired 
pulse TMS and these were compared with those of 10 age-matched healthy control 
subjects in order to determine whether the changes in cortical excitability are 
asymmetrical.  In addition, clinical and objective measures of PD severity were 
measured and correlated with the cortical excitability parameters in order to examine 
whether a relationship can be found between these measures.   
 
4.2 METHODS 
4.2.1 Subjects  
Studies were undertaken in a convenience sample of 12 non-tremor-dominant PD 
patients referred to the Movement Disorders Unit, Westmead Hospital, Sydney 
Australia (10 males, 2 females, median age 63 years, age range 46-82) and the mean 
disease duration was 4.5 years (median 4.5 years), Table 4-1.  The diagnosis of PD 
was based on the United Kingdom Parkinson’s Disease Society Brain Bank clinical 
diagnostic criteria for PD [126]. More affected side was determined on the basis of 
clinical examination using Part 3 of Movement Disorder Society - Unified 
Parkinson’s Disease Rating Scale (MDS-UPDRS) [127].  In patients with 
symmetrical signs, the side of onset was designated as the more affected side. Motor 
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cortex contralateral to more affected upper limb was designated as the more affected 
cortex.  
Studies were performed in a practically defined off state in the morning after an 
overnight withdrawal of medications, at least 12 hours after the last dose.  All subjects 
gave informed consent to the procedures, which were approved by the Sydney 
Western Area Health Service Human Research Ethics Committee. 
Each subject underwent TMS, clinical assessments, and objective measures of 
bradykinesia and rigidity.  All assessments were performed on both sides in a single 
study visit over approximately 2 hours. 
 
 
Table 4-1  Disease duration refers to the period from symptom onset to date of assessment.  
MDS-UPDRS refers to part 3 of Movement Disorder Society - Unified Parkinson’s Disease 
Rating Scale score ON-medication and OFF-medication.  H&Y refers to Hoenh and Yahr.  Total 
daily dose of medications was assessed in each patient. 
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4.2.2 Clinical staging of PD 
In 9 patients the left side was the more affected side and in 3 the right side.  Each 
subject was assessed clinically using Part 3 of MDS-UPDRS.  Upper limb 
bradykinesia scores were calculated for each subject based on the sum of three 4-point 
measures of finger tapping, hand movements and pronation-supination movements of 
hands, with a score of 0 indicating absence of bradykinesia, and a score of 12, severe 
bradykinesia.  Rigidity was assessed at the wrists, with 0 being no rigidity and 4, 
severe rigidity.  
 
4.2.3 Experimental set up 
Objective measures – Rigidity 
Objective rigidity was measured according to the method described by Fung et al. 
[128].  Briefly, subjects were seated comfortably in a dental chair, with their forearms 
resting in a splint and their hands semi-pronated in a manipulandum.  Motion of the 
wrist was restricted to a horizontal plane, negating the effects of gravity. 
The manipulandum was mounted on the vertically orientated shaft of a printed circuit 
torque motor (PMI Motion Technologies JR16M4CH-1, Commack, NY, USA) so that 
the wrist joint was overlying the axis of rotation.  Torque output was directly 
proportional to the current supplied to the motor.  During rigidity measurements, 
resistive torque was assessed by monitoring and converting this current to a 
proportional voltage.  A precision potentiometer mounted to the lower end of the 
motor shaft signalled angular position. 
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The torque motor was operated as a position servo to generate sinusoidal 
perturbations of 60° peak-to-peak amplitude about the 0° position, i.e., ±30°.  Ten 
non-contiguous 5-sec epochs were recorded for each objective rigidity measurement 
with the total recording time taking approximately 2 minutes.  During each 5-sec 
epoch, a 3-sec interval of oscillation at 1.0 Hz was either preceded or followed by a 
contiguous 2-sec interval of oscillation at 1.5 Hz.  The number of epochs beginning 
with each frequency (1.0 Hz or 1.5 Hz) was equal and the order of presentation of 
epochs varied in a pseudorandom fashion.  Resistive torque was rectified and 
integrated with respect to time, yielding the scalar equivalent of angular impulse 
referred to as angular impulse score [128].  
 
Objective measures - Bradykinesia  
Bradykinesia was measured for each hand with a timed tapping task as described by 
Nutt et al. [129].  The subjects were seated on a chair in front of a table on which was 
positioned two electronic touch pads 20 cm apart.  Subjects were instructed to tap the 
two touch pads alternately as fast as possible for 60 seconds and the number of taps 
and changes in the rate of tapping between the first and the last 15 second epochs 
were measured for each hand.   
 
TMS procedure 
Cortical excitability was assessed by measuring the resting motor threshold (RMT), 
magnetic evoked potential (MEP) amplitude, short interval intracortical inhibition 
(SICI), intracortical facilitation (ICF) and cortical silent period (CSP). 
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Cortical excitability studies were undertaken by applying a 90 mm circular coil to the 
motor cortex with currents generated by two high-power magnetic stimulators 
connected via a BiStim (Magstim Co., Whitland, South West Wales, UK).  
Conditioning and test stimuli could be independently set and delivered through one 
coil.  Paired-pulse threshold tracking TMS was undertaken according to a previously 
reported technique [26].  Briefly, the motor evoked potential (MEP) amplitude was 
fixed and changes in the test stimulus intensity required to generate a target response 
of 0.2 mV (± 20%), when preceded by a sub-threshold conditioning stimuli at various 
interstimulus intervals (ISIs), were measured [26].  The MEP response was recorded 
over the right abductor pollicis brevis (APB).  RMT was defined as the stimulus 
intensity required to maintain this target MEP response (0.2 mV). SICI was 
determined by using sub-threshold conditioning stimuli (70% RMT) at increasing ISIs 
as follows: 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 7 ms. ICF was measured at ISIs of 10, 15, 
20, 25 and 30 ms.  
Stimuli were delivered sequentially as a series of three channels: channel 1 tracked 
the stimulus intensity required to produce the unconditioned test response (i.e., RMT); 
channel 2 monitored the response to the subthreshold conditioning stimulus; and 
channel 3 tracked the stimulus required to produce the target MEP when conditioned 
by a stimulus equal in intensity to that on channel 2.  The EMG activity was 
monitored continuously to ensure the absence of voluntary background activity 
affecting MEP amplitude. Response from channel 2 was subtracted from channel 3 to 
eliminate contribution from conditioning stimulus. Stimuli were delivered every 5 
seconds (stimulus delivery was limited by the charging capability of the BiStim 
system) and the computer advanced to the next ISI only when tracking was stable.   
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SICI was measured as the increase in the test stimulus intensity required to evoke the 
target MEP.  Inhibition was calculated off-line as follows [26]:  
Inhibition = (Conditioned test stimulus intensity – RMT)/RMT * 100 
Facilitation was measured as the decrease in the conditioned test stimulus intensity 
required to evoke the target MEP.  
 
Cortical silent period refers to a period of electrical silence in a contracting muscle, 
and was measured from the onset of the MEP to the return of EMG activity with 
magnetic stimulus intensity set to 140% RMT [26, 49].  
 
4.2.4 STATISTICAL ANALYSIS 
Cortical excitability was compared to 10 age-matched control subjects (5 males, 5 
females, median age 65 years, age range 46-72) using one-way ANOVA.  Paired 
samples t-test was used to compare the side-to-side differences in both PD and age 
matched control subjects. Correlations between excitability indices and objectives 
measures of bradykinesia and rigidity were analysed using Spearman’s rank 
correlation coefficient.  Results were expressed as mean ± standard error of the mean 
and a probability (P) value of less than 0.05 was considered significant.  For the 
correlation studies between cortical excitability changes and motor function, because 
there is a large inter-subject variability, side-to-side differences in cortical excitability 
were correlated with side-to-side differences in motor function. 
 
    
60 
4.3 RESULTS 
4.3.1 Clinical measures of disease of severity (modified MDS-UPDRS)  
The average MDS-UPDRS score in the OFF state was 18.3 (range = 4 - 40), 
consistent with mild-moderate disease.  Mean upper limb MDS-UPDRS bradykinesia 
score was 3.9 ± 0.8 on the more affected side and 2.3 ± 0.6 on the less affected side, 
with the mean difference being 1.7 ± 0.5, (**P < 0.01, Figure 4-1A) indicating 
significant asymmetry of motor impairment between the more and less affected sides.  
Furthermore, there was a significant difference in MDS-UPDRS rigidity scores 
between the more and less affected sides (more-affected side = 1.4 ± 0.3; less-affected 
= 0.8 ± 0.3, mean difference = 0.7 ± 0.2, **P < 0.01, Figure 4-1B).   
 
 
Figure 4-1  There were significant differences in mean upper limb MDS-UPDRS subscores for 
(A) bradykinesia; **P < 0.01 and (B) rigidity; **P < 0.01 
 
4.3.2 Objective bradykinesia - hand tapping speed 
In the control subjects, there was a significant difference in tapping speed as analysed 
by hand dominance (dominant side = 254.5 ± 7.0/minute; non-dominant side = 226.3 
± 5.5, ** P <0.002, Figure 4-2A).   
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In the PD subjects, there was a significant difference in hand tapping speeds between 
the more and less affected sides (more-affected side = 168.1 ± 11.3/minute; less-
affected side = 196.3 ± 12.0 **P < 0.01, Figure 4-2B). 
 
4.3.3 Objective rigidity 
In age-matched control group, there was no difference in rigidity between the 
dominant and non-dominant hands (dominant side = 0.24 ± 0.02 Nm; non dominant 
side = 0.20 ± 0.02 Nm, P = 0.07 ). 
Interestingly, PD subjects also did not show significant differences in objective 
rigidity between the more and less affected sides (more affected side = 0.22 ± 0.02 
Nm; less affected side = 0.23 ± 0.02 Nm, P = 0.41).  
 
 
Figure 4-2  Comparison of average hand tapping speeds (TS).  (A) There was a significant 
difference in TS between the dominant and non-dominant sides in age-matched normal control 
subjects; **P < 0.01; (B) Similarly, there was a significant difference in TS between the more 
affected and less affected sides in PD subjects; **P < 0.01 
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4.3.4 Cortical excitability measurements 
Motor thresholds and magnetic evoked potentials 
In the age-matched controls, RMT was comparable between the dominant and non-
dominant sides (dominant = 58.69 ± 3.0%; non dominant = 59.23 ± 2.9%).  MEP 
amplitude was comparable (dominant = 2.29 ± 0.76; non-dominant = 2.36 ± 0.60) as 
was MEP latency (dominant = 23.27 ± 0.49; non-dominant = 23.28 ± 0.48). 
In the PD subjects, the RMT (more-affected = 48.3 ± 2.2%; less-affected = 49.2 ± 
2.1%, P = 0.66) and MEP amplitude (more affected side = 1.18 ± 0.25mV; less 
affected side = 1.13 ± 0.14, P = 0.83) were similar between the more and less-affected 
sides suggesting that side-to-side differences did not lead to significant differences in 
these measures of cortical excitability. 
However, there were significant group differences in RMT (F(43) = 5.069, P = 0.005) 
although no such differences were found in MEP amplitude (F(42) = 2.468, P = 0.08). 
 
Cortical silent period duration 
In the age-matched controls, CSP duration was comparable between the dominant and 
non-dominant sides (dominant = 223.4 ± 10.7 ms; non-dominant = 227.5 ± 10.7 ms, P 
= 0.3, Figure 4-3A).  However, in PD subjects, CSP duration was significantly 
reduced on the more affected side compared with the less affected side (more affected 
= 201.4 ± 10 ms, less-affected = 214.3 ms; mean difference -12.8 ± 4.5 ms, *P < 0.02, 
Figure 4-3B).  
There was no significant difference in CSP duration between the PD and age-matched 
control groups (F(42) = 1.259, P = 0.30).  
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Figure 4-3	  	  Cortical silent period (CSP) duration, as measured from the onset of the motor 
evoked potential to the beginning of electromyography (EMG) activity, was significantly reduced 
in PD subjects; *P<0.05. 
 
SICI 
In the age matched control subjects, SICI was comparable between the dominant and 
non-dominant sides (dominant = 6.35 ± 2.24 %; non-dominant = 7.84 ± 1.91 %, P = 
0.57, Figure 4-4A). 
In the PD group, there was a significant side-to-side difference in SICI (more-affected 
= 9.01 ± 2.32 %; less-affected = 13.07 ± 2.27 %, mean difference = -4.06 ± 1.72 %, 
*P < 0.04, Figure 4-4B).  However, no statistically significant difference was detected 
between the PD and age-matched control subjects (F(43) = 1.721 P=0.178). 
ICF 
In the age-matched controls, there was no significant difference in ICF between the 
dominant and non-dominant sides (dominant side  =  -0.91 ± 2.17 %; non-dominant 
side = -2.74 ± 2.07 %, mean difference = 1.83 ± 2.60 %, P = 0.50, Figure 4-5A). 
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Likewise, in the PD subjects there was no significant statistical difference between the 
more and less affected sides (more affected side = 4.22 ± 1.23; less affected = 3.15 ± 
1.35, mean difference = 1.07 ± 1.35, P = 0.44, Figure 4-5B).   
However, ICF was statistically significantly reduced in the PD subjects compared 
with the age matched control subjects (F(41) = 3.678, *P = 0.02). 
 
Figure 4-4  Short interval intracortical inhibition (SICI) was comparable between the PD and 
normal control (NC) subjects (Not shown).  SIC was comparable between the dominant and non-
dominant sides in normal control subjects (A), but significantly reduced on the more affected side 
relative to the less affected side in PD patients (B); *P<0.05 
 
 
 
 
Figure 4-5  ICF was significantly reduced in the PD compared with NC subjects (Not shown), but 
there was no significant difference between the dominant and non-dominant sides in NC (A) or 
between the more and less affected sides in PD subjects (B). 
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4.3.5 Relationship between clinical measures of disease severity and cortical 
excitability in PD subjects 
In PD subjects, measures of bradykinesia did not correlate with absolute SICI values 
from the corresponding hemisphere, likely owing to large variability in SICI between 
subjects.  However, there was a significant correlation between interhemispheric 
differences in SICI (more affected side – less affected side) and side-to-side 
differences in MDS-UPDRS bradykinesia  (ρ = -0.59, *P < 0.05, Figure 4-6), with the 
correlation being stronger with the hand tapping speeds (ρ = -0.80, **P< 0.002, 
Figure 4-7).  In contrast, there was no such correlation in age-matched control 
subjects despite there also being significant side-to-side difference in hand tapping 
speed (ρ = -0.25, P < 0.49).   
The side-to-side differences in hand tapping speed did not correlate with 
interhemispheric differences in CSP (ρ = -0.284, P = 0.37) or ICF (ρ = 0.172, P = 
0.59) in PD subjects.  Similarly, there was no significant correlation between hand 
tapping speed and side-to-side difference in CSP duration (ρ = -0.201, P = 0.60) in the 
age matched control group. 
In terms of rigidity, there was no correlation between side-to-side differences in SICI 
and angular impulse scores (ρ = 0.495, P = 0.102) or MDS-UPDRS rigidity scores (ρ 
= 0.004, P = 0.99).  However the correlation between side-to-side difference in ICF 
and objective rigidity approached statistical significance (ρ = -0.519, P = 0.084) in PD 
subjects. 
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4.4 DISCUSSION 
The present study has identified significant cortical dysfunction in PD.  Specifically, 
there was a significant reduction in ICF in PD subjects compared with age matched 
control subjects. Additionally, there was a significant reduction in SICI and CSP 
duration on the more affected side compared with the less affected side in PD 
subjects, although there was no difference between PD and age-matched normal 
control subjects overall.  It is notable that in PD, the side-to-side difference in SICI 
correlated with side-to-side difference in clinical and objective measures of 
bradykinesia, while there was no such side-to-side difference in SICI in the age-
matched normal control subjects despite there being a clear side-to-side difference in 
hand tapping speeds between the dominant and non-dominant hands.  Taken together 
our findings suggest that asymmetry in cortical function (SICI and CSP) is a 
pathophysiological feature of PD and is reflective of asymmetry in motor impairment, 
although it remains to be determined whether this represents a primary abnormality 
underlying asymmetry in bradykinesia or instead is compensatory. 
To our knowledge, the present study is the first to apply the threshold tracking paired-
pulse TMS to examine interhemispheric differences in cortical excitability in PD and 
age-matched normal subjects.  The threshold tracking technique has the advantage of 
overcoming marked variability in MEP amplitudes from stimulus to stimulus seen 
with conventional paired stimulation TMS.  With this technique, the target MEP is set 
in a steep portion of the nonlinear SR curve (i.e. 0.2mV) and changes in stimulus 
intensity required to elicit this target MEP are measured, thereby avoiding the marked 
variability in MEP amplitudes and measuring changes in stimulus intensity [26, 57] 
that are less prone to random variation.  This speeds up the recording process and 
allows studies to be completed in a relatively short period of time, making it 
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particularly suited to subjects who have difficulty tolerating prolonged recording 
sessions or fluctuating motor function such as those with PD. 
 
 
Figure 4-6  There was a significant correlation between interhemispheric differences in SICI 
(more affected side – less affected side) and side-to-side differences in MDS-UPDRS bradykinesia 
scores; ρ = -0.59; *P < 0.05. 
 
 
To date, cortical excitability studies in PD patients using the paired pulse TMS have 
revealed mixed results. Several studies have reported reduced ICF in PD subjects [31, 
78-80], but others have failed to find significant reduction [7, 76].  Similarly, SICI 
and CSP duration have been reported to be either normal or reduced, but it is likely 
that cortical excitability changes depend on the clinical state in which the recordings 
are made.  For instance, SICI and CSP duration have both been reported to be reduced 
in the OFF-medication state and to normalise with acute as well as chronic 
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dopaminergic therapy [7, 28, 45, 130, 131], with some studies even reporting 
lengthening in CSP duration in patients who are on high doses of dopaminergic 
therapy [7, 132]. 
 
 
Figure 4-7  There was highly significant correlation between interhemispheric differences in SICI 
and corresponding side-to-side differences in hand tapping speeds; ρ = -0.80; **P< 0.002. 
 
Our finding of significantly reduced SICI on the more affected side compared with 
the less affected side within PD subjects is in contrast to previous studies [6, 78].  
However, the fact that the magnitude of asymmetry in SICI correlated with 
corresponding asymmetry in objective bradykinesia in the present study supports the 
validity of our findings and the apparent discrepancy between the results of ours and 
others’ studies could be explained by differences in TMS technique and study 
population. 
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We cannot completely discount the fact that the side-to-side asymmetry in SICI in PD 
patients in the present study was due to the underlying rigidity as minor increases in 
muscle tone has a significant influence on cortical excitability [28], with the side-to-
side differences in SICI merely reflecting the differences in muscle tone.  However, in 
contrast to this previous study [28] in our cohort of PD patients, MTs and MEPs were 
comparable between the more and less affected sides suggesting that differences in 
tone did not have significant influence on the side-to-side differences in SICI.  
Furthermore, there was no correlation between corresponding side-to-side differences 
in clinical and objective measures of rigidity and SICI. 
 
What is the significance of the cortical excitability changes in PD subjects? 
In the present study, ICF was significantly reduced in PD subjects compared with 
healthy age-matched control subjects despite the fact that the PD subjects had 
relatively mild disease.  Previously, it has been demonstrated that deficits in muscle 
activation [81] and movement scaling [82] are pathophysiological mechanisms 
underpinning bradykinesia.  Furthermore, it has been shown that MT is normal at rest, 
but increases during voluntary contraction, resulting in a fewer motor neurons being 
recruited for an intended movement, i.e. relative failure of voluntary facilitation may 
be a possible mechanism of bradykinesia in PD [34, 37].  The reduced ICF in PD 
subjects could be due to reduced facilitatory inputs involved in ICF and underlie these 
two key deficits in PD bradykinesia although the fact that there was lack of 
correlation between ICF and hand tapping speed suggests that other as yet unclarified 
mechanisms are also likely to be involved.   
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The fact that there was no significant side-to-side difference in ICF in both 
physiological state and PD suggests that ICF has no direct influence on hand 
dominance or asymmetry in bradykinesia, but our finding of significantly reduced 
SICI on the more affected side relative to the less affected side in PD subjects, 
suggests that it could contribute to greater reduction in movement speed and 
amplitude on the more affected side by allowing the “unhelpful” competing motor 
circuits to be active during an intended movement thereby interrupting the focus of 
neuronal activity onto the appropriate pathways [56].  However, the fact that there 
was no significant difference in SICI and CSP between the PD and healthy age-
matched control groups in the present study suggests that it is unlikely to be the 
primary mechanism underlying bradykinesia although it could still contribute to the 
asymmetry in motor function in PD.  Instead the asymmetry in SICI could represent a 
compensatory phenomenon in which intracortical inhibition is reduced in order to 
facilitate voluntary movement production by countering deficits in muscle activation 
and movement scaling as well as relative failure of voluntary facilitation.    If indeed 
relatively reduced SICI on the more affected side is a compensatory phenomenon, it 
might be a process whereby inhibitory pathways are down-regulated in an attempt to 
reverse the reduced facilitation (ICF) that is thought to underlie bradykinesia.  The 
fact that SICI and CSP are reduced on the more affected side relative to the less 
affected side in PD but still normal when compared to age-matched control subjects 
would be consistent with the notion that reduced SICI appears first on the more 
affected side and later spreads to involve the less affected side, and suggests that this 
is a late and inadequate compensatory phenomenon.  
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It is well accepted that SICI is mediated by cortical inhibitory neurons acting via 
GABAA receptors [58, 63, 102, 133, 134], as evidenced by pharmacological studies 
revealing that GABA agonists, benzodiazepines, enhance SICI [23].  Therefore the 
finding of significantly reduced SICI on the more affected hemisphere relative to the 
less affected side in the present cohort of PD subjects suggest relative dysfunction of 
GABA-ergic inhibitory neurons on the more affected hemisphere acting via GABAA 
receptors.  In addition to dysfunction of GABAA circuits, the findings from this study 
suggest concomitant dysfunction of GABAB circuits.  Specifically, the cortical silent 
period is mediated by cortical inhibitory mechanisms acting via GABAB circuits and 
local spinal inhibitory processes [50, 52].  Given that CSP duration was also 
significantly reduced on the more affected side relative to the less affected side, 
relative dysfunction of cortical GABA-ergic processes acting via GABAB receptors 
may in part account for this finding [50, 52].  
 
4.4.1 Limitations of this study 
As patients with persistent moderate or severe tremor were excluded from this study, 
a question arises as to whether this resulted in selection of an atypical PD cohort.  
This is unlikely because all patients fulfilled the UK clinical criteria for IPD [126] and 
approximately 25% of pathologically proven cases do not experience tremor [135].  A 
further question is whether the findings of this study can be extended to subjects who 
have tremor or dyskinesia. 
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4.5 CONCLUSION 
The present study has identified significant side-to-side differences in cortical 
excitability between the more and less affected sides in PD patients but not in age 
matched controls.  This was despite the fact that both groups had similar side-to-side 
differences in hand tapping speed, suggesting that asymmetry in cortical excitability 
might be a pathophysiological feature of PD.  However, it remains to be determined 
whether this represents a primary abnormality contributing to asymmetrical 
bradykinesia or instead is compensatory.  
    
73 
Chapter 5 Effects of levodopa on cortical 
excitability in Parkinson’s disease 
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ABSTRACT 
Cortical excitability studies were undertaken using threshold tracking paired-pulse 
TMS in 19 PD subjects before and after their usual morning levodopa medication and 
the results were compared with 10 age-matched control subjects.  All patients 
underwent assessment of their MDS-UPDRS, timed hand tapping task and angular 
impulse score as described in Chapter 4 in the OFF and ON-medication states.  Each 
set of assessments was completed within 2 hours. 
There was a significant improvement in the hand tapping speed (TS) after medications 
in line with the UPDRS results (TSOFF = 184.3 ± 12.2, TSON = 202.3 ± 11.7, TSDIFF = 
-18.0 ± 4.6, P = 0.001).  ICF was reduced in the PD patients compared with the 
controls with the difference being greater and approaching statistical significance in 
the OFF than ON-medication state (one-way ANOVA P = 0.12), but there was no 
significant difference in ICF between the OFF and ON-medication states.  There was 
no significant difference in SICI between the PD and control subjects (one-way 
ANOVA P = 0.54) nor was there difference between OFF and ON-medication states.  
There was a correlation between SICI and decrement in hand tapping speed in the 
OFF-medication state (ρ = -0.59, P = 0.01, Figure 5-11A).  In addition, there was 
correlation between ICF and decrement in hand tapping speed in the OFF-medication 
state (ρ = -0.47, P < 0.05, Figure 5-12).  There was no significant correlation between 
SICI, ICF and CSP with TS and objective rigidity.  The findings suggest that reduced 
SICI is a compensatory rather than primary pathophysiological change and is 
involved in modifying the rate of decrement in repetitive movements that characterise 
parkinsonian bradykinesia. 
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5.1 INTRODUCTION 
Cortical excitability studies in PD using paired-pulse transcranial magnetic 
stimulation (TMS) have provided reasonably firm evidence that short interval 
intracortical inhibition (SICI) is reduced [7, 11, 30, 32, 33, 74] but intracortical 
facilitation (ICF) has been variably reported [31, 78-80] [7, 76], making it difficult to 
draw firm conclusions about cortical excitability changes and their role in PD 
pathophysiology.   
In Chapter 4 (Side-to-side study), cortical excitability studies undertaken in a cohort 
of PD patients in the off-medication state and age-matched healthy control subjects 
demonstrated significantly reduced ICF and relatively reduced SICI on the more 
affected side compared with the less affected side in PD patients.  Notably, there was 
significant correlation between interhemispheric asymmetry in SICI and side-to-side 
asymmetry in hand tapping speed in PD patients but not in age-matched healthy 
control subjects despite the fact that the control subjects also demonstrated significant 
side-to-side asymmetry in hand tapping speed on the basis of hand dominance.  The 
findings from Chapter 3 are consistent with the notion that reduced ICF and relatively 
reduced SICI on the more affected side are pathophysiological features of PD.   
 
Studies on effects of levodopa therapy on cortical excitability provide not only further 
information about the cortical excitability changes in PD but also insights into the 
significance of cortical excitability changes in PD.  A number of previous studies 
have demonstrated that levodopa therapy restores the reduced SICI [7, 30, 74], 
perhaps via its direct or indirect effects on disordered intracortical excitability [136], 
but the influence of levodopa therapy on ICF has been inconsistent and has yet to be 
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fully clarified.  For example, one study reported reduced SICI and ICF in the off-
medication state, but only SICI and not ICF was restored in the on-medication state 
[79] while another study reported normal SICI and reduced ICF in the off-medication 
state with restoration of the reduced ICF with levodopa therapy [80].  The restoration 
of intracortical inhibition (SICI) and facilitation (ICF) under effective levodopa 
therapy is assumed to be due to changes in the basal ganglia where the drugs exert 
their effect, but whether the cortical excitability changes represent a primary or 
secondary compensatory phenomenon and furthermore whether these are beneficial or 
harmful remains to be resolved.    
The primary objective of the present study was to examine the effect of levodopa 
therapy on cortical excitability using the threshold tracking paired-pulse TMS and the 
relationship between cortical excitability and motor function in patients with PD.  The 
effects of levodopa therapy can be divided into short duration response (SDR) and 
long duration response (LDR) in which the SDR is the transient improvement in 
motor function lasting minutes to hours that occurs after each dose of levodopa and 
the LDR, an anti-parkinsonian action that decays over hours-days.  Hence the present 
study examined the cortical excitability and motor function associated with the SDR 
and LDR of levodopa therapy in order to gain further insights into the significance of 
cortical excitability changes in PD.  Specifically, the SDR was assessed by examining 
the motor function and cortical excitability in the OFF-medication state and 1 hour 
after levodopa while LDR was assessed by examining the time course of changes in 
motor function and cortical excitability during prolonged withdrawal of levodopa. 
Importantly, the present study sought to investigate whether a single dose of levodopa 
therapy exerts an influence on cortical excitability and if so, whether a relationship 
exists between the changes in cortical excitability and changes in objective and 
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clinical measures of motor function.  To date, threshold tracking paired-pulse TMS 
has not been utilised in the study of cortical excitability in PD patients and hence the 
pattern of cortical excitability changes obtained from the present study would provide 
further insights into the significance of these changes.  
 
5.2 METHODS 
5.2.1 Experiment 1 – Short duration response to levodopa 
Subjects 
Studies were undertaken in a convenience sample of 19 non-tremor-dominant PD 
patients recruited from the Movement Disorders Unit, Westmead Hospital, Sydney 
Australia (14 males, 5 females, median age 61.7 years (age range 46-74), See Table 5-
1).  All patients satisfied the United Kingdom Parkinson’s Disease Society Brain 
Bank clinical diagnostic criteria for PD [126].  The accuracy of the PD diagnosis was 
proven by subsequent long-term clinical follow-up and positive response to levodopa 
treatment.  Studies were performed in a practically defined off state in the morning 
after overnight withdrawal of medications, at least 12 hours after the last dose and 
then repeated on the same morning 1 hour after patients were administered their usual 
first dose of levodopa therapy.  All patients gave informed consent to the procedures, 
which were approved by the Sydney Western Area Health Service Human Research 
Ethics Committee. 
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Table 5-1  Patient characteristics.  LD denotes levodopa and doses indicate total daily doses.  
Hand dominance was determined using the Edinburgh Handedness Index. 
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Experimental set up 
Each subject underwent a set of assessments before and after their usual morning 
levodopa medication in the following order. 
i. Clinical assessment of PD 
ii. Objective assessment of bradykinesia and rigidity 
iii. Cortical excitability with threshold tacking paired-pulse TMS 
 
All neurophysiological assessments were made on the more-affected side as assessed 
clinically and in those with symmetrical disease, the side that first manifested 
symptoms was considered as the more affected side.  Each set of assessments was 
completed within 2 hours. 
 
Clinical Assessment of PD 
Each subject was clinically assessed using Part III (motor section assessment) of 
Movement Disorder Society - Unified Parkinson’s Disease Rating Scale (MDS-
UPDRS) [127].  Upper limb bradykinesia scores were calculated for each subject 
based on the sum of three 4-point measures of finger tapping, hand movements and 
pronation-supination movements of hands, with a score of 0 indicating absence of 
bradykinesia, and a score of 12, severe bradykinesia.  Rigidity was assessed at the 
wrist, with 0 being no rigidity and 4 being severe rigidity. 
 
Objective assessments 
Rigidity 
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Objective rigidity was measured using a torque motor as described by Fung et al. 
[128].  Briefly, subjects were seated comfortably in a dental chair, with their forearms 
resting in a splint and their hands semi-pronated in a manipulandum and resistive 
torque was measured using a torque motor (PMI Motion Technologies JR16M4CH-1, 
Commack, NY, USA), which was operated as a position servo to generate sinusoidal 
perturbations of 60° peak-to-peak amplitude about the 0° position.  Ten non-
contiguous 5-sec epochs were recorded for each objective rigidity measurement and 
during each 5-sec epoch, a 3-sec interval of oscillation at 1.0 Hz was either preceded 
or followed by a contiguous 2-sec interval of oscillation at 1.5 Hz.  The number of 
epochs beginning with each frequency was equal and the order of presentation of 
epochs varied in a pseudorandom fashion.  Resistive torque was rectified and 
integrated with respect to time, yielding the scalar equivalent of angular impulse 
referred to as angular impulse score [128]. 
 
Bradykinesia 
Objective bradykinesia was measured with a timed tapping task as described in 
Chapter 3.  The subjects tapped two touch pads positioned 20 cm apart with one hand 
as fast as possible for 60 seconds and the total number of taps, i.e., tapping speed 
(TS), was recorded before and after levodopa.  The rate of change in hand tapping 
speed was calculated for each patient by working out the slope of change in hand 
tapping frequency.  As a negative slope indicated decrement in hand tapping 
frequency, this was converted to a positive value and referred to as decrement.  
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Cortical excitability 
Cortical excitability was assessed by measuring the resting motor threshold (RMT), 
magnetic evoked potential (MEP) amplitude, short interval intracortical inhibition 
(SICI), intracortical facilitation (ICF) and cortical silent period (CSP). 
Briefly, threshold tracking TMS was adapted to the paired-pulse paradigm to 
investigate SICI in which a subthreshold (70% resting motor threshold, RMT) 
conditioning stimulus preceded a suprathreshold test stimulus.  The interstimulus 
intervals (ISIs) between the conditioning and test stimuli were 1, 1.5, 2, 2.5, 3, 3.5, 4, 
5, 7 ms.  Intracortical facilitation was assessed at ISIs 10,15,20,25 and 30 ms.  For the 
purposes of threshold tracking, resting motor threshold (RMT) was defined as the 
stimulus intensity required to produce a 0.2-mV (peak-to-peak) magnetic evoked 
potential (MEP) amplitude.  Stimuli were delivered sequentially as a series of three 
channels recorded the following: channel 1 tracked the stimulus intensity required to 
produce the unconditioned test response (i.e., RMT); channel 2 monitored the MEP 
response to the subthreshold conditioning stimulus; and channel 3 tracked the 
stimulus required to produce the target MEP when conditioned by a stimulus equal in 
intensity to that on channel 2.  Stimuli were delivered every 5 seconds (stimulus 
delivery was limited by the charging capability of the BiStim system) and the 
computer advanced to the next ISI only when tracking was stable. 
SICI was measured as the increase in the test stimulus intensity required to evoke the 
target MEP.  Facilitation was measured as the decrease in the conditioned test 
stimulus intensity required to evoke the target MEP. 
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Cortical silent period refers to a period of electrical silence in a contracting muscle, 
and was measured from the onset of the MEP to the return of EMG activity with 
magnetic stimulus intensity set to 140% RMT [26, 49]. 
 
5.2.2 Experiment 2 – Long duration response to levodopa 
Long duration response of levodopa was examined in 3 patients with early PD (Table 
5-2).  Baseline motor and cortical excitability assessments were made after an 
overnight withdrawal of levodopa after which patients were given their usual morning 
dose of levodopa and measurements were made periodically over days until there was 
a sustained decline in motor function.  On Day 1, measurements were made at 30-
minute intervals for the first 4 hours, then 60-minute intervals for the next 4 hours, 
and from Day 2, measurements were made twice daily approximately 6 hours apart, 
e.g. 8am and 4pm, until there was a sustained decline in motor function. Cortical 
excitability was compared between the more and less affected cerebral hemispheres as 
well as being correlated with hand tapping speed.  Because of the need to acquire data 
in a timely manner in order to accommodate making repeated measurements every 30 
minutes, a modified TMS protocol was applied in which the interstimulus intervals 
(ISIs) between the conditioning and test stimuli were selected at 1, 2.5 and 3 ms for 
SICI and ICF had to be omitted.  Further, bradykinesia was measured with hand 
tapping speed but objective rigidity was not measured.  All experimental techniques 
were otherwise identical to Experiment 1. 
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Table 5-2  Patient characteristics for long duration response to levodopa. 
 
 
5.3 STATISTICAL ANALYSIS 
Cortical excitability in PD patients was compared between the OFF and ON-
medication states using the paired samples t-test and these results were compared to 
71 healthy controls (36 males, 35 females, mean age 48.3 years, age range 23-83) 
using one-way ANOVA.  Correlations between excitability indices and objective 
measures of bradykinesia and rigidity were analysed using Spearman’s rank 
correlation coefficient.  Results were expressed as mean ± standard error of the mean 
and a probability (P) value of less than 0.05 was considered significant. 
 
5.4 RESULTS 
5.4.1 Experiment 1 
Clinical Staging of Parkinson’s Disease 
There was a significant difference in MDS-UPDRS Part III scores between the OFF-
medication and ON-medication states (UPDRSOFF = 20.2 ± 2.5, UPDRSON = 10.8 ± 
2.0, UPDRSDIFF = 9.4 ± 1.4, P < 0.0001, Figure 5-1A), indicating a significant 
medication effect.  Specifically, bradykinesia and rigidity subscales of MDS-UPDRS 
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showed highly significant differences between OFF and ON-medication states 
(UPDRS-bradyOFF = 6.2 ± 1.0, UPDRS-bradyON= 3.5 ± 0.7, UPDRS-bradyDIFF = 2.7 ± 
0.6, P = 0.001, Figure 5-1B; UPDRS-rigidOFF = 1.8 ± 0.3, UPDRS-rigidON = 0.9 ± 0.2, 
P = 0.001, Figure 5-1C). 
 
 
Figure 5-1 Mean MDS-UPDRS scores before  and 1 hour after levodopa (A); mean MDS-UPDRS 
scores for bradykinesia(B) and rigidity(C). 
 
Objective motor assessment 
A. Bradykinesia 
There was a significant improvement in the hand tapping speed (TS) after medications 
in line with the UPDRS results (TSOFF = 184.3 ± 12.2, TSON = 202.3 ± 11.7, TSDIFF = 
-18.0 ± 4.6, P = 0.001, Figure 5-2), confirming that tapping speed is a reliable 
measure of bradykinesia as utilized in previous published papers [129].  In the OFF-
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medication state, there was greater decrement in hand tapping speed than in the ON-
medication state although this was not statistically significant (DecrementOFF = 8.7 × 
10-3 ± 1.4 × 10-3, DecrementON = 5.1 × 10-3 ± 2.8 × 10-3, Mean difference = 3.6 × 10-3 
± 2.1 × 10-3, P = 0.11, Figure 5-3).   
 
B. Rigidity 
There was no significant improvement in the objective rigidity scores in the ON-
medication state despite the fact that there was a significant improvement in UPDRS 
rigidity scores (RigidityOFF = 0.242 ± 0.016 Nm/sec, RigidityON = 0.241 ± 0.020 
Nm/sec, RigidityDIFF = 0.001 ± 0.013 Nm/sec, P = 0.92, Figure 5-3). 
 
 
Figure 5-2 Hand tapping speed before and 1 hour after medication 
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Figure 5-3  Decrement in hand tapping speed 1 hour after levodopa 
 
 
                
 
Figure 5-4  Objective rigidity before and 1 hour after medication 
 
 
 
Cortical excitability measures 
A. MT and MEPs 
Resting motor threshold (RMTOFF = 49.6 ± 2.1%, RMTON = 50.2 ± 1.9%, RMTDIFF = 
-0.7 ± 0.8, P = 0.41, Figure 5-5A) and MEP amplitudes (MEPOFF = 4.7 ± 0.4 mV, 
MEPON = 4.9 ± 0.4 mV, MEPDIFF = -0.2 ± 0.3 mV, P = 0.58, Figure 5-5B) were 
comparable between the OFF-medication and ON-medication states.  One-way 
ANOVA showed that there was a significant reduction in both MTs (P = 0.004) and 
MEPs (P < 0.0001) in the PD patients compared with healthy control subjects. 
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Figure 5-5  Motor threshold (MT) and motor evoked potential (MEP) amplitude before and 1 
hour after levodopa 
 
B. CSP 
The cortical silent period was similar between the OFF-medication and ON-
medication states (CSPOFF = 202.35 ± 10.06 ms, CSPON = 201.23 ± 8.04 ms, CSPDIFF 
= 1.12 ± 9.62 ms, P = 0.91, Figure 5-6).  When compared with the control group, 
there was no significant difference (CSPOFF = 202.4 ± 10.1 ms, CSPON = 201.2 ± 8.0, 
CSPNC = 211.9 ± 3.1 ms, one-way ANOVA P = 0.28). 
 
C. SICI  
There was no significant difference in SICI between the PD and control subjects 
(SICIOFF = 8.26 ± 1.64 %, SICION = 8.65 ± 1.55 %, SICINC = 9.83 ± 0.69 %, one-way 
ANOVA P = 0.54) nor was there difference between OFF and ON-medication states 
(SICIOFF = 8.26 ± 1.64 %, SICION = 8.65 ± 1.55 %, SICIDIFF = -0.39 %, P = 0.76, 
Figure 5-7). 
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D. ICF  
ICF was reduced in the PD patients compared with the controls with the difference 
being greater and approaching statistical significance in the OFF than ON-medication 
state (ICFOFF = 2.20 ± 1.39 %, ICFON = 1.68 ± 1.21 %, ICFNC = -0.53 ± 0.72 %, one-
way ANOVA P = 0.12, Figure 5-8), but there was no significant difference in ICF 
between the OFF and ON-medication states (ICFOFF = 2.20 ± 1.39 %, ICFON = 1.68 ± 
1.21 %, ICFDIFF = 0.52 ± 1.45 %, P = 0.72, Figure 5-8). 
  
 
 
Figure 5-6  CSP before and 1 hour after levodopa. 
 
 
 
Figure 5-7  SICI before and 1 hour after levodopa. 
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Figure 5-8  ICF before and 1 hour after levodopa 
 
 
Correlation between clinical and objective measures of motor function  
In the OFF-medication state, the correlation between TSOFF and total UPDRSOFF 
approached statistical significance (ρ = -0.46, P = 0.06, Figure 5-9A) although there 
was no significant correlation between TSOFF and bradykinesia sub-scale of MDS-
UPDRS (i.e. UPDRS-bradyOFF) (ρ = -0.35, P = 0.17, Figure 5-9B).  In the ON-
medication state, there was a significant correlation between TSON and UPDRSON (ρ = 
-0.64, P = 0.006, Figure 5-10A) as well as with UPDRS-bradyON (ρ = -0.72, P = 
0.001, Figure 5-10B).  On the other hand, objective rigidity scores did not correlate 
with any of the clinical measures of disease severity (MDS-UPDRS), including the 
bradykinesia and rigidity subscales.  
 
Correlation between motor function and cortical excitability 
There was a correlation between SICI and decrement in hand tapping speed 
(decrement) in the OFF-medication state (ρ = -0.59, P = 0.01, Figure 5-11A) and the 
same correlation approached statistical significance in the ON-medications state (ρ = -
0.43, P < 0.08, Figure 5-11B).  In addition, there was correlation between ICF and 
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decrement in the OFF-medication state (ρ = -0.47, P < 0.05, Figure 5-12), but not in 
the ON-medication state.  There was no significant correlation between SICI, ICF and 
CSP with TS and objective rigidity. 
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Figure 5-9  Correlation between hand tapping speed and (A) MDS-UPDRS (P = 0.06) and (B) 
bradykinesia subscale of MDS-UPDRS (P = 0.17) in the OFF-medication state. 
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Figure 5-10  Correlation between hand tapping speed and (A) MDS-UPDRS (P = 0.006) and (B) 
bradykinesia subscale of MDS-UPDRS (P = 0.001) in the ON-medication state. 
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Figure 5-11  Correlation between SICI and (A) decrement in hand tapping speed in the OFF-
medication state (P = 0.01) and (B) ON-medication state (P < 0.08).  
    
94 
 
Figure 5-12  Correlation between ICF and decrement in hand tapping speed in the OFF-
medication state (P < 0.05) 
 
 
 
 
5.4.2 Experiment 2 
Assessments were made until day 5 in subject 1, day 26 in subject 2 and day 8 in 
subject 3.  Side-to-side asymmetry and changes in TS reflected asymmetry in akinesia 
rather than handedness in all three patients.   
 
Objective motor assessment - hand tapping speed 
Subject 1 
The TS increased transiently for approximately 3.5 hours after levodopa on the more-
affected side with the expected wearing off of the SDR whereas the TS returned to the 
baseline after approximately 8 hours on the less-affected side.  Thereafter, the TS 
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remained stable for 24 hours before decreasing below that of the baseline on the 
more-affected side while it remained stable on the less-affected side for the duration 
of the assessment (Figure 5-13). 
 
Subject 2  
The TS increased rapidly after LD and thereafter remained elevated and did not return 
to the baseline until day 24 on the more-affected side although there was a gradual 
decline over time (Figure 5-14).  
Subject 3   
There was a transient rise in TS after levodopa.  Thereafter the TS gradually reached a 
plateau after 24 hours on the more-affected side and after 78 hours on the less-
affected side (Figure 5-15).  
 
Cortical Excitability - SICI 
Subject 1 
On the more affected side, SICI transiently increased after levodopa, peaking at 1.25-
hours and staying elevated until 3.5-hours following which it progressively decreased 
over time following the variations in TS (Figure 5-16A).  On the less-affected side, 
SICI appeared to increase after levodopa but the difference was smaller compared 
with the more-affected side (Figure 5-16B).  Comparison between the more and less-
affected sides showed significantly reduced SICI on the more-affected side (mean 
difference = 7.23 ± 2.37 %, P < 0.05 – paired samples t test, Figure 16C).  
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Subject 2  
There was a transient increase in SICI after levodopa on both the more and less-
affected sides, which peaked over 1-3 hours and appeared to match the increase in TS 
(Figure 5-17A,B).  Thereafter, there were marked fluctuations in SICI although there 
appeared be a trend for SICI to remain relatively stable over time.  Comparison 
between the more and less-affected sides showed no significant difference in SICI. 
 
Subject 3 
On the more-affected side SICI increased and peaked over 2 hours after levodopa 
before returning to the baseline over the next 1.5 hours.  Thereafter SICI remained 
relatively stable over time although at times there were marked fluctuations (Figure 5-
18A).  On the less-affected side, there was no particular pattern of change (Figure 5-
18B).  There was no significant side-to-side difference in SICI. 
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Figure 5-13  Time profile of changes in hand tapping speed for the more and less affected sides – 
Patient 1. 
 
 
 
 
 
Figure 5-14  Time profile of changes in hand tapping speed for the more and less affected sides – 
Patient 2. 
 
 
 
 
Figure 5-15  Time profile of changes in hand tapping speed for the more and less affected sides – 
Patient 3. 
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Figure 5-16  Time profile of changes in SICI and hand tapping speed in Patient 1 – more affected 
side (A), less affected side (B).  Note tapping rate was converted into a percentage of the 
maximum tapping rate and plotted against time.  The graph is broken into 2 segments; the short 
segment reflects the SDR and the long segment reflects the LDR 
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Figure 5-17  Time course of changes in Tapping rate and SICI in Patient 2 – more affected side 
(A), less affected side (B). 
 
 
 
 
 
Figure 5-18  Figure 5-19  Time profile of changes in SICI and hand tapping speed in Patient 3 – 
more affected side (A), less affected side (B). 
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5.5 DISCUSSION 
5.5.1 Experiment 1 - SDR 
The key finding from Experiment 1 was that in PD patients, both ICF and SICI 
correlated significantly with decrement in hand tapping speed in the OFF-medication 
state and the correlation between SICI and decrement in hand speed approached 
statistical significance in the ON-medication state (P < 0.08).  ICF tended to be 
reduced in the OFF-medication state and subsequently increased towards that of 
control subjects in the ON-medication state when measured 1-hour after the dose, but 
there was no significant reduction in SICI in the OFF-medication state nor was there 
significant effect in the ON-medication state despite there being a clear improvement 
in clinical and objective measures of bradykinesia. 
 
In the side-to-side study (Chapter 4), patients with PD had relatively reduced SICI on 
the more affected side compared with the less affected side although there was lack of 
overall difference in SICI between PD and healthy age-matched control subjects.  
Given that SICI has been reported as being reduced in PD in a number of studies [7, 
11, 30, 32, 33, 74], it is possible that the normal SICI seen in the present study and 
Chapter 4 could have been due to the patients having relatively mild disease, however 
a relationship has never been demonstrated between SICI and measures of disease 
severity in previous cortical excitability studies in PD.  Rather, the results from the 
present study support the alternative finding of normal SICI in PD [31, 72, 73] 
particularly as these result were replicated using a different technique (threshold 
tracking paired-pulse TMS) to previous studies, and shed further light on the role of 
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SICI in the pathophysiology of bradykinesia in PD although the results cannot be 
generalised to those with advanced PD. 
 
The fact that there was positive correlation between SICI and decrement in hand 
tapping speed implies that SICI tends to be normal in patients with relatively fast 
decrement in hand tapping speed and reduced in those with slow decrement.  Given 
that parkinsonian bradykinesia is characterized by decrement in speed and amplitude 
of repetitive movements, the findings from the present study point to reduced SICI 
being a compensatory phenomenon in which SICI is reduced in order to facilitate 
voluntary movement production by countering deficits in muscle activation and 
movement scaling as well as relative failure of voluntary facilitation [37], but failure 
of compensatory decrease in SICI in those with greater decrement.  Further, if SICI 
indeed were a primary phenomenon involved in the pathophysiology of bradykinesia, 
it would have been expected to match and possibly precede the improvement in motor 
function after a single dose of levodopa but no such change in SICI was observed, 
arguing against this possibility.  The results support the finding of reduced ICF as 
well as relatively reduced but overall normal SICI on the more affected side in the 
side-to-side study (Chapter 4) as being compensatory changes. 
 
A possible explanation for the lack of changes in SICI despite significant 
improvement in hand tapping speed after a single dose of medication is that 
alterations in SICI reflect long-term changes in cortical function and hence a single 
dose of levodopa may not influence the longstanding changes.  This would be 
supported by the fact that the study on Stiff-man syndrome (Chapter 2, [137]) 
revealed markedly reduced SICI even on high doses of benzodiazepines and in the 
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absence of any symptoms or evidence of exaggerated exteroceptive reflexes that 
characterise the condition.  Another possibility is that the magnitude of change in 
hand tapping speed was too small in the present study for differences in SICI to 
become apparent. 
 
In terms of RMTs and MEPs, there was a significant difference between PD patients 
and healthy control subjects, which needs further explanation.  PD patients had lower 
RMTs and MEPs, which could be explained by PD patients having increased rigidity 
akin to maintaining a weak voluntary contraction during assessment of activated 
motor threshold, but the fact that there was no medication effect on these measures 
despite significant clinical improvement in rigidity would argue against this 
possibility and having a significant influence on the results of the present study.  
 
5.5.2 Experiment 2 - LDR 
The key finding from Experiment 2 was that there was a relatively consistent transient 
increase in SICI after a single dose of LD, matching the improvement in hand tapping 
speed despite the fact that only three patients were assessed.  Following this, 
prolonged assessment revealed mixed findings with Patients 2 and 3 displaying 
marked fluctuations in SICI over the course of days but Subject 1 displaying 
progressive reduction in SICI following the variations in TS, reflective of the hand 
tapping speed.  The results suggest that there are short-term alterations in SICI after 
each dose of LD although it may be difficult to capture this from “one-off” recording 
given that changes were seen 1-2 hours after LD as well as the fact that there can be 
marked fluctuations from one recording to the next.   
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Hence the lack of changes in SICI in Experiment 1 in which SICI was assessed 1-hour 
after levodopa may have been due to the fact that changes in SICI take time to 
develop as suggested in Experiment 2, which demonstrated relatively consistent 
increase in SICI after levodopa on the more affected side but the time course of this 
change differed amongst patients and usually peaked over 1-3 hours.  Therefore it is 
possible that Experiment 1 failed to capture significant changes in SICI simply 
because of the timing of the assessment.   
 
Interestingly, there were mixed changes in SICI over the course of days, with Patients 
2 and 3 demonstrating fluctuations although overall there appeared to be a trend for 
SICI to progressively decrease over time.  The changes in SICI were more prominent 
on the more affected side compared with the less affected side in agreement with the 
results from Chapter 3, which demonstrated significant relative reduction in SICI on 
the more affected side compared with the less affected side.  The results from the 
present study suggest that SICI changes over minutes-hours after levodopa reflective 
of SDR of levodopa and that it may follow rather than precede the motor 
improvement as improvement in the hand tapping speed was not associated with 
changes in SICI in Experiment 1.  Overall, the results from the present study point to 
reduced SICI being a compensatory change. 
 
5.5.3 Limitations 
Experiment 2 was limited by the small number of patients and findings need to be 
replicated in a larger number of patients but this was a difficult study to perform on 
two accounts.  Firstly it is a time consuming and technically challenging study, as 
patients need to be assessed over a number of days and each block of assessments 
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needs to be completed within 30 minutes.  Secondly, patients need to be willing to 
stop their medications for a prolonged period of time and make themselves available 
for several days in a row, which essentially excludes those who are in employment, 
i.e. relatively young patients with PD.  In addition, time course of changes in ICF 
after levodopa was not addressed in this study and future studies assessing the time 
course of changes in ICF would provide further insights into the significance of 
cortical excitability changes in PD. 
 
5.6 CONCLUSION 
The findings suggest that reduced SICI is a secondary compensatory rather than a 
primary pathophysiological change and is involved in modifying the rate of 
decrement in repetitive movements that characterise parkinsonian bradykinesia. 
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Chapter 6 CORTICAL EXCITABILITY IN 
PATIENTS WITH PARKINSON’S DISEASE ON 
LEVODOPA CARBIDOPA INTESTINAL GEL 
THERAPY 
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Abstract 
This study assessed whether there are corresponding changes in cortical excitability 
with changes in motor function and plasma levels of levodopa in advanced PD 
patients.  Six patients who have been established on levodopa carbidopa intestinal gel 
(LCIG) therapy for more than 12 months underwent assessment of their cortical 
excitability and clinical objective measures of bradykinesia and rigidity as well as 
plasma levodopa levels.  Studies were performed under two conditions, i.e. with the 
LCIG pump OFF then ON and serial measurements being made every 30 minutes.  As 
expected there was rapid decline in plasma levodopa levels but there were no 
significant reduction in hand tapping rate.  SICI was significantly reduced in PD 
patients and progressively became more significant at each subsequent time points. 
There was a statistically significant correlation between mean SICI and mean 
levodopa concentration, but there was no correlation between mean SICI and mean 
hand tapping speed or between mean levodopa concentration and mean hand tapping 
speed.  The results from this study suggest that SICI is reduced in patients with severe 
PD and in addition SICI positively correlates with plasma levodopa levels.  Taken 
together, the findings suggest that SICI is influenced by the disease severity as well as 
plasma levodopa levels. 
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6.1 INTRODUCTION  
Short interval intracortical inhibition (SICI) has been extensively investigated in both 
the OFF and ON-medication states in PD but the findings have been somewhat 
inconsistent.  A number of groups have reported reduced SICI in the untreated or 
OFF-medication state particularly in those with more advanced disease, and further 
that the reduced SICI normalises with treatment with dopaminergic therapy [7, 30, 74, 
78, 138] whilst other studies have failed to detect any changes in SICI [31, 72] or any 
improvement with dopaminergic therapy.  This inconsistency is most likely due to the 
fact that the studies have been undertaken using different TMS techniques as well as 
non-uniform patient populations with varying disease stage and severity.  In Chapter 4 
in which cortical excitability was compared between the more and less clinically 
affected sides, ICF was significantly reduced in PD patients compared with normal 
control subjects while SICI was significantly reduced on the more affected side 
although still normal when compared with normal control subjects.  Of importance, 
the side-to-side asymmetry in SICI correlated with corresponding side-to-side 
asymmetry in hand tapping speed, thereby suggesting a possible role of reduced SICI 
in the pathophysiology of asymmetry in bradykinesia.  In Chapter 5, which examined 
the effect of levodopa therapy on cortical excitability, the findings from the first study 
were extended.  Specifically, there was significant correlation between SICI and 
decrement in hand tapping in the OFF-medication state with the same correlation 
approaching significance in the ON-medication state.  Of note SICI was not 
significantly reduced in PD patients in the OFF-medication state and oral levodopa 
did not alter the SICI when measured after 1 hour despite the fact that there was 
significant improvement in motor function as measured by MDS-UPDRS and timed 
hand tapping speeds.  There are two plausible explanations for the lack of differences 
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in SICI between the PD and normal control subjects.  The first is that the cohort of PD 
subjects in our studies had relatively mild disease and therefore the magnitude of 
changes in SICI was difficult to detect, particularly as it has been suggested to be 
more pronounced in those with more severe disease [138] although there is some 
evidence for reduced SICI in PD patients with relatively mild disease [78].  The 
second explanation is that levodopa does not exert acute changes in cortical 
excitability although there are previous reports of alteration in cortical excitability 
with both acute and chronic dopaminergic therapies [7, 28, 45, 130, 131].   
 
An interesting phenomenon in the therapeutics of PD is the long duration response 
(LDR).  The lack of fluctuation in patients with early PD treated with levodopa is 
attributed to the LDR, an antiparkinsonian action that decays over hours to days 
[129].  It has been suggested that disease progression with wearing-off fluctuations 
appear when the LDR begins to shorten thereby uncovering the short duration 
response (SDR), which is dependent on plasma levodopa concentration [123, 129].  In 
the advanced stages of PD, the LDR becomes progressively reduced and patients 
become increasingly dependent on the SDR for motor symptom control and therefore 
the pharmacokinetics of levodopa becomes a critical factor for stable motor control as 
fluctuations in plasma concentrations of levodopa are accompanied by fluctuations in 
motor performance [139, 140].  One of the strategies against motor fluctuations is to 
extend the response to each dose of levodopa with catechol-O-methyl transferase 
(COMT) inhibitors and monoamine oxidase-B (MAO-B) inhibitors, whereby 
elimination half-life of levodopa is increased, thus prolonging the availability of 
levodopa to the brain [141, 142], i.e. extending the SDR.  However, it has been 
demonstrated that the main hurdle in achieving a stable plasma level of levodopa in 
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PD is delayed gastric emptying, which interferes with the delivery of oral levodopa to 
the jejunum, where it is absorbed into the blood stream.  Importantly, PD subjects 
with motor fluctuations have gastric emptying half-times which are more than double 
those of PD subjects without motor fluctuations [143], but steady plasma levels of 
levodopa can be achieved with duodenal administration of LD with corresponding 
reduction in motor fluctuations [144].  Levodopa carbidopa intestinal gel (LCIG) 
therapy delivers levodopa directly to the proximal jejunum via a percutaneous 
gastrojejunostomy tube using a portable infusion pump and the pharmacokinetic 
studies have demonstrated that steady plasma levodopa levels similar to those 
achieved with IV levodopa administration can be achieved [145, 146].  Indeed LCIG 
therapy has been proven to be an effective therapy for advanced PD patients 
experiencing motor fluctuations and dyskinesia and the results from some centres 
have been in the order of those seen with deep brain stimulation [147, 148].  Given 
that LCIG therapy can provide stable and predictable plasma concentrations of 
levodopa, it offers a unique opportunity in which to gain further insights into cortical 
excitability changes in advanced PD.  Specifically, it provides the ability to assess the 
relationship between cortical excitability and plasma levodopa concentration and 
further, the relationship between these measures and motor function, which would 
help to gain further insights into the significance of cortical excitability changes in PD 
pathophysiology.  Therefore, the present study assessed the time course of changes in 
SICI and motor function in relation to plasma levodopa levels in advanced PD 
patients who have been stabilised on LCIG therapy.  The patients were first assessed 
with the LCIG pump ON, following which LCIG was switched OFF and serial 
measurements were made to document the time profile of changes in plasma levodopa 
level, cortical excitability changes and motor function. 
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6.2 HYPOTHESES 
i. There are corresponding changes in cortical excitability with changes in motor 
function and plasma levels of levodopa in advanced PD patients. 
ii. The relationship between motor function and cortical excitability are more 
prominent in PD subjects with advanced disease, i.e. those who have lost the 
LDR. 
iii. Changes in cortical excitability precede changes in motor function.  
 
6.3 METHODS  
6.3.1 Subjects 
Studies were undertaken in 6 non-tremor dominant advanced PD patients treated with 
LCIG therapy recruited from the Movement Disorders Unit at Westmead Hospital, 
Sydney Australia (6 males, median age 64 years (age range 59-67), See Table 6-1.  
All patients satisfied the United Kingdom Parkinson’s Disease Society Brain Bank 
clinical diagnostic criteria for PD [126].  The accuracy of the PD diagnosis was 
proven by long-term clinical follow-up and positive response to levodopa treatment.  
    
111 
 
 
Table 6-1  Patient characteristics. 
 
 
 
 
Figure 6-1  Experimental procedures.  LCIG – levodopa carbidopa intestinal gel; LD – levodopa; 
mAIMS – modified Abnormal Involuntary Movement Scale. 
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6.3.2 Experimental procedure 
Studies were performed under two conditions: 
 LCIG pump ON then 
 LCIG pump OFF 
 
Each patient underwent a set of clinical and neurophysiological assessments every 30 
minutes (i.e. 30 minute blocks), comprising of the following measures: 
TMS – Bilateral cerebral cortex 
Timed hand tapping – (Bilateral) 
Objective rigidity – (Unilateral) 
Plasma levodopa level  
MDS-UPDRS (rigidity/bradykinesia 3.3-3.8) and modified AIMS (items 5-7) 
 
The first set of assessments was made with the LCIG pump ON, following which the 
LCIG pump was switched OFF and serial assessments were made every 30 minutes 
for 4 hours or until patients could no longer tolerate being in the OFF-medication state 
and parkinsonian (Fig. 6-1).  All patients gave informed consent to the procedures, 
which were approved by the Sydney Western Area Health Service Human Research 
Ethics Committee. 
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6.3.3 Clinical assessment of disease severity 
Each subject was assessed clinically using the Part III (motor section assessment) of 
Movement Disorder Society - Unified Parkinson’s Disease Rating Scale (MDS-
UPDRS), which was adapted to the study by examining only the upper limb 
bradykinesia and rigidity [127].  Upper limb bradykinesia scores were calculated for 
each subject based on the sum of three 4-point measures of finger tapping, hand 
movements and pronation-supination movements of hands, with a score of 0 
indicating absence of bradykinesia, and a score of 12, severe bradykinesia.  Rigidity 
was assessed at the wrists, with 0 being no rigidity and 4 being severe rigidity. 
 
Modified AIMS (mAIMS), a validated 5-point scale was used to assess dyskinesia 
from three body regions, including upper and lower extremities and trunk.  Each body 
region was rated on a 5 point anchored scale: 
 
  0 – None 
  1 – Minimal  
  2 – Mild 
  3 – Moderate 
  4 – Severe 
 
This resulted in a maximum score of 12 for the three body regions.  A score of 3 was 
taken as being minimal dyskinesia and 9 as moderate dyskinesia. 
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6.3.4 Cortical excitability 
Cortical excitability was assessed by measuring the resting motor threshold (RMT), 
magnetic evoked potential (MEP) amplitude and short interval intracortical inhibition 
(SICI).  Intracortical facilitation (ICF) was not assessed for the purpose of this study. 
 
Briefly, threshold tracking TMS was adapted to the paired-pulse paradigm to 
investigate SICI in which a subthreshold (70% resting motor threshold, RMT) 
conditioning stimulus preceded a suprathreshold test stimulus. The interstimulus 
intervals (ISIs) between the conditioning and test stimuli were limited to 1, 1.5, 2, 2.5, 
3 ms in order to assess the SICI in a timely manner and allow each set of recordings to 
be completed within a 30 minute block.  For the purposes of threshold tracking, 
resting motor threshold (RMT) was defined as the stimulus intensity required to 
produce a 0.2-mV (peak-to-peak) magnetic evoked potential (MEP) amplitude.  
Stimuli were delivered sequentially as a series of three channels: channel 1 tracked 
the stimulus intensity required to produce the unconditioned test response (i.e., RMT); 
channel 2 monitored the response to the subthreshold conditioning stimulus; and 
channel 3 tracked the stimulus required to produce the target MEP when conditioned 
by a stimulus equal in intensity to that on channel 2.  Stimuli were delivered every 5 
seconds and the computer advanced to the next ISI only when tracking was stable.  
SICI was measured as the increase in the test stimulus intensity required to evoke the 
target MEP.  
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6.3.5 Hand tapping speed  
Objective bradykinesia was measured with a timed tapping task as described in 
chapter 3.  The subjects were asked to tap two touch pads positioned 20 cm apart as 
fast as possible for 60 seconds with one hand at a time and tapping speed (TS, 
taps/minute) was recorded for each hand. 
 
6.3.6 Plasma levodopa concentration 
Proteins in plasma were precipitated with TCA (5%) and plasma cleared by 
centrifugation at 10,000 x gav for 5 minutes and filtration of supernatant through a 
0.22µM filter.  The supernatant was then diluted 1 in 10 with water and HPLC 
analysis of levodopa performed on a LC-10A HPLC system (Shimadzu).  System 
operation was automated by Class LC-10 software.  Chromatography was on a 
Zorbax ODS column (250 mm x 4.6 mm) with a Pelliguard guard column (LC-18).  
The mobile phase was a gradient of solvent A (10 mM sodium phosphate buffer pH 
2.5 with 100 mM sodium perchlorate) and solvent B (80% v/v methanol) at a flow 
rate of 1 ml/ min.  The following gradient was used: isocratic elution with 84% A for 
12 minutes then to 80% A over 8 minutes; elution at 80% A for 3 minutes before 
changing to 50% A in 3 minutes; isocratic elution at 50% A for a further 3 minutes 
then re-equilibration with 100% A for 10 minutes.  The eluate was monitored by UV 
(Shimadzu, SPD-M10A) and fluorescence detectors (Shimadzu, RF-10AXL).  The 
fluorescence detector was set at an excitation wavelength of 280 nm and an emission 
wavelength of 320 nm.  The elution position of levodopa was defined on the basis of a 
purified standard.  Confirmation of peak identity was obtained by spiking plasma 
samples with purified levodopa and observing an increase in the area under the curve 
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of the identified peak.  A standard curve was constructed that showed a linear 
relationship between the area under the curve of the levodopa peak on the HPLC 
chromatogram and the concentration of standard injected.  Levodopa concentration in 
the samples was then quantified from the standard curve.  An additional standard was 
run every third sample. 
 
6.3.7 Data analysis 
All assessments from individual patients were grouped into 30-minute blocks 
according to the elapsed time from the start of the initial assessment with pump ON at 
time zero.  Accordingly, “T0” was designated to indicate the time period from 0 to 29 
minutes and all assessments made in this time period was grouped into T0.  As the 
LCIG pump was switched off after this period and the next set of measurements were 
made 30 minutes after switching off, “T1” denoted the time period between 60 
minutes and 89 minutes from time zero.  Accordingly, “T2” denoted the time period 
between 90 and 119 minutes and “T4”, the time period between 150 and 179 minutes 
from time zero (Figure 6-1).  Due to the small number of patients, both the right and 
left sided assessments were pooled together for the analysis. 
 
6.4 STATISTICAL ANALYSIS 
Repeated measures ANOVA analysis was the most suitable statistical method for the 
study, but this could not be used because each set of measurements could not be 
completed within the allocated 30 minute blocks due to patient related and technical 
factors.  Therefore differences in group means at each time point were compared with 
each other as well as with 71 healthy control subjects (36 males, 35 females, mean 
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age 48.3 years, age range 23-83) using a one-way ANOVA.  Multiple comparisons 
were conducted with Tukey’s post-hoc analysis.  Correlations between excitability 
parameters and clinical and objective measures of bradykinesia and rigidity were 
analysed by Spearman’s rank test.  A probability (P) value of less than 0.05 was 
considered statistically significant.  Results are expressed as mean ± standard error of 
the mean. 
 
6.5 RESULTS 
Three out of six (3/6) patients had mild-moderate dyskinesia at T0 (mean mAIMS = 
5.3, range 1-8) but this only precluded one patient from undergoing the TMS studies 
at T0 because of excessive EMG artefact.  Only two out of six (2/6) patients were able 
to continue with the data collection beyond 150 minutes from when the LCIG pump 
was switched off, i.e. T4 (180 minutes from time zero) because of inability to tolerate 
being OFF-medication and parkinsonian although neither the MDS-UPDRS nor hand 
tapping speeds changed significantly.  However, the two patients who were able to 
tolerate being OFF-medication continued up to T8 and T9.  
 
6.5.1 Clinical measures of disease of severity (modified MDS-UPDRS) 
There were no significant differences in group means in MDS-UPDRS scores 
between different time points (F 6,47 = 0.875, P = 0.521, Figure 6-2A).  Further, there 
were no significant differences in group means in the bradykinesia subscale of MDS-
UPDRS, (F 6,47 = 0.776, P = 0.593, Figure 6-2B) as well as the rigidity subscale (F 6,47 
= 0.901, P = 0.502, Fig. 6-2B).   
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Figure 6-2  Clinical measures of disease severity.  (A) means MDS-UPDRS scores at different 
time points; (B) mean MDS-UPDRS bradykinesia and rigidity scores. 
    
119 
6.5.2 Modified AIMS 
Mean mAIMS was 6.3 (range 1-8) at T0 consistent with mild-moderate dyskinesia in 
the pump ON state while it was 3.8 (range 0-8) at T1 and 3 (range 0-7) at T2 
consistent with minimal-mild dyskinesia.  Patient 4 who had moderate dyskinesia at 
T0 with a mAIMS score of 8, had a progressive reduction in hand tapping speed over 
time despite improvement in dyskinesia, likely suggesting that dyskinesia did not 
significantly influence the hand tapping speed.  
 
6.5.3 Objective bradykinesia - hand tapping speed 
There were no significant differences in group means in hand tapping speeds across 
different time points (F 5,49 = 0.438, P = 0.820, Figure 6-3) despite statistically 
significant reduction in LD concentration from T0 to T4 (Figure 6-4). 
 
6.5.4 Plasma Levodopa Concentration 
There was progressive reduction in levodopa concentrations from T0 to T5 with 
statistically significant differences in mean levodopa concentrations across time 
points (F 5,23 = 5.339, P = 0.002).  Levodopa concentrations were significantly higher 
at T0 compared to those measured at T3 (4.47 ± 1.10, P = 0.014), T4 (3.26 ± 0.74, P = 
0.004) and T5 (3.04 ± 0.84, P = 0.006); see Figure 6-4. 
    
120 
 
Figure 6-3  Time course of changes in hand tapping speed. 
 
 
 
 
  
Figure 6-4  Time course of changes in levodopa level. 
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6.5.5 Cortical excitability measures 
Motor thresholds 
There were no significant differences in mean RMT between different time points in 
PD patients (F 4,37 = 0.401, P = 0.806, Figure 5A).  However, there were highly 
significant differences in RMT between PD patients and normal control subjects at 
baseline (F 5,97 = 14.372, P < 0.000, Figure 5B).  
 
Cortical silent period duration 
There was no significant difference in CSP duration between PD patients and normal 
control subjects (F 5,94 = 0.895, P = 0.488, Figure 6A).  However, there appeared to be 
a trend for reduction in CSP duration from T0 (223.0 ± 19.3 ms) to T4 (181.2 ± 14.3 
ms) within PD patients although this was not statistically significant (F 4,33 = 1.022, P 
= 0.411, Figure 6B). 
 
SICI 
There were statistically significant differences in SICI between PD patients and 
normal control subjects (F 5,96 = 10.415, P < 0.000, Figure 7A).  SICI was 
significantly reduced in PD patients and progressively became more significant at 
each subsequent time points, i.e. SICI at T2 (2.07 ± 2.02 %, P = 0.001), T3 (2.40 ± 
2.12 %, P = 0.002) and T4 (-2.55 ± 2.42 %, P < 0.000) were significantly reduced 
compared with normal control subjects (10.29 ± 0.71 %), Figure 7B.   
Within PD patients, there were statistically significant differences in SICI between 
different time points (F 4,37 = 2.668, P = 0.032).  Specifically, SICI at T4 (-2.55 ± 2.42 
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%) was significantly reduced compared to T0 (7.39 ± 1.97 %, P = 0.029) and 
approached statistical significance with respect to T1 (6.30 ± 2,14 %, P = 0.079).  
There were no statistically significant differences in SICI between other time points, 
i.e. T1, T2 and T3 compared with T0 (Figure 6-7B).   
When the dataset was further analysed to look for differences between the more and 
less affected sides, there was no statistically significant difference in SICI (F 1,41 = 
0.623, P = 0.434). 
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Figure 6-5  Resting motor threshold (RMT).  Time course of changes in mean RMT (A); 
Comparison of RMT between PD and NC subjects (B). 
 
 
    
124 
  
 
 
 
 
 
 
Figure 6-6  Cortical silent period (CSP) duration.  Time course of changes in mean CSP duration 
(A); Comparison of CSP duration between PD and NC subjects (B). 
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Figure 6-7  Short interval intracortical inhibition (SICI).  Time course of changes in mean SICI 
(A); Comparison of SICI between PD and NC subjects (B). 
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6.5.6 Relationship between Cortical excitability and hand tapping speed and 
plasma levodopa concentration 
For correlation analysis, right and left sided data were combined and averaged before 
being analysed as a group.   
 
SICI 
There was a statistically significant correlation between mean SICI and mean 
levodopa concentration (r = 0.900, P = 0.037, Figure 6-8).  However, there was no 
correlation between mean SICI and mean hand tapping speed (r = -0.5, P = 0.391) or 
between mean levodopa concentration and mean hand tapping speed (r = -0.543, P = 
0.266). 
 
 
 
Figure 6-8  Correlation between mean SICI and mean levodopa concentration. 
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CSP 
There was no correlation between CSP duration and levodopa concentration (r = 
0.543, P = 0.27) nor was there correlation between CSP duration and TS (r = -0.371, P 
= 0.47). 
 
Clinical measures 
In terms of clinical measures, there was no correlation between levodopa 
concentration and MDS-UPDRS (r = -0.377, P = 0.461).  Similarly, there was no 
correlation between LD concentration and MDS-UPDRS subscales, bradykinesia (r = 
-0.486, P = 0.329) and rigidity (r = -0.406, P = 0.425). 
 
6.6 DISCUSSION 
The key finding from the present study was that SICI correlated with mean levodopa 
concentration but not with hand tapping speed in subjects with advanced PD treated 
with LCIG therapy.  In other words, there was a progressive reduction in levodopa 
concentration over time as expected when the LCIG pump was switched OFF and this 
was matched by progressive reduction in SICI.  Further, SICI was significantly 
reduced in PD patients compared to normal control subjects in the OFF-LCIG phase 
with the difference becoming significant at T4 compared with T0, suggesting 
progressive reduction in SICI in the OFF-LCIG phase.  However, the present study 
failed to detect a corresponding reduction in hand tapping speed over the same time 
interval despite the patients having been off LCIG therapy for more than 2 hours and 
the mean plasma LD concentration decreasing by more than 70% although one out of 
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the six patients showed a progressive reduction in hand tapping speed which 
plateaued at about 60 minutes after the LCIG pump was switched OFF. 
 
The pattern of changes in SICI seen in the present study needs some discussion.  The 
progressive reduction in SICI which developed during the OFF-LCIG phase did not 
appear until T2 or T3, i.e. 60-120 minutes after the LCIG pump was switched off and 
the greatest reduction was seen at T4, suggesting that changes in SICI take substantial 
time to develop, perhaps following rather than preceding change in motor function.  
The implication is that changes in SICI may not be detectable if subjects are assessed 
approximately 60 minutes after levodopa although disease severity also has some 
influence on whether reduced SICI can be detected or not [138].  This is in agreement 
with the findings from the study in Chapter 5 in which there was no significant 
increase in SICI when measured 60 minutes after patients’ usual morning dose of 
levodopa and the increases being seen only 60 - 180 minutes after levodopa.  The fact 
that reduced SICI was consistently detected in the PD patients with more advanced 
disease in the present study despite only examining six patients compared with 
significantly higher numbers of patients in the preceding experiments (Chapters 4-5) 
would support the hypothesis that the finding of reduced SICI is dependent on disease 
severity and would be in agreement with the findings of Hanajima and Ugawa [138] 
 
It has been suggested previously that the finding of an reduced SICI in PD patients 
was dependent on the intensity of the conditioning stimulus and one particular study 
reported that SICI became reduced only when the CSI was increased above 80% of 
RMT, consistent with the idea that reduced SICI arises from changes in the 
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excitability of pathways that mediate short interval intracortical facilitation (SICF) [5, 
76].  The fact that the present study detected significantly reduced SICI with the CSI 
set at 70% RMT rather than above 80% in a group of PD patients with advanced 
disease raises the possibility that the threshold of intracortical facilitatory pathways 
becomes progressively decreased with disease progression although the other 
possibility that the threshold of inhibitory pathways becomes increased cannot be 
completely excluded.   
It is noteworthy that there was no progressive reduction in hand tapping speed when 
the LCIG pump was switched OFF despite the fact that all of the patients had 
advanced disease and could not tolerate being in the OFF-medication state.  There 
was no apparent reduction in hand tapping speed in the majority of patients at T4 even 
when there had been a significant reduction in the levodopa concentration.  This is 
incompatible with previous pharmacokinetic studies, which demonstrated that motor 
function mirrors the plasma levels of levodopa [140, 149].  How does one reconcile 
the lack of changes in the hand tapping speed despite significant reduction in plasma 
levodopa level?  A tantalizing suggestion is that the long-term LCIG therapy with 
continuous dopaminergic stimulation somehow resulted in pharmacodynamic changes 
of levodopa and augmented the LDR [129], thereby improving the motor fluctuations 
and indeed it has been demonstrated that LCIG therapy improves motor function and 
quality of life in patients with advanced PD [150].  Another possibility is that the hand 
tapping speed was influenced by dyskinesia.  Dyskinesia scores improved from being 
mild-moderate at the beginning of the study with the LCIG pump ON to being 
minimal-mild after the pump was switched OFF and hence it is conceivable that the 
hand tapping speed was lower than expected for a given levodopa level at the 
beginning of the study and the expected improvement in hand tapping speed with the 
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improvement in dyskinesia was offset by wearing off of levodopa.  Yet another but 
less likely possibility is that the hand tapping speed may not be a sensitive measure of 
bradykinesia, but it has been previously demonstrated that it can reliably detect 
changes in motor function [123, 129] and indeed the experiment on effects of 
levodopa (Chapter5) demonstrated clear differences in hand tapping speed based on 
the medication state. 
 
Side-to-side comparisons 
In the present study, there was no significant side-to-side difference in cortical 
excitability but this was likely due to the small number of subjects in this study and 
does not invalidate the previous finding of significant relative reduction in SICI on the 
more affected side (Chapter 4).   
In terms of the reduced RMT in our subjects, TMS studies in PD patients who have 
had deep brain stimulation (DBS) surgery have shown that RMT in OFF-DBS 
condition is not significantly altered by switching to ON-DBS state or administration 
of the dopamine agonist apomorphine, despite clear improvements in motor function 
[39], suggesting that RMT is not related to motor performance in PD unlike in normal 
controls where MT correlates with fine finger movements [27],  and hence that 
clinical manifestations of PD are not primarily the result of any deficit in the 
excitability of individual motor neurons and their local density.  Therefore, it was 
unlikely for the reduced RMT to have significantly influenced the results.  
The fact that SICI correlated with plasma levodopa level rather than hand tapping 
speed raises questions about its role in the PD pathophysiology.  However, 
interpretation of this result is not straight forward due to the fact that most of the 
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patients had at least mild-moderate dyskinesia in the present study and as yet the 
effects of dyskinesia on cortical excitability remains unclarified. 
 
6.6.1 Limitations of the study 
The main limitation of this study is the small number of patients and hence the 
findings cannot be generalised and has to be replicated in a larger group of patients.  
However the fact that consistent and significant findings were detected even with the 
small number of patients support the validity of the findings from this study.  
 
6.7 CONCLUSION 
SICI is reduced in patients with PD but the degree to which this is reduced appears to 
depend on disease severity, being more likely to be observed in those with advanced 
disease.  Further, SICI correlates with plasma levels of levodopa.  Taken together, the 
findings suggest that SICI is influenced by both the disease severity as well as plasma 
levodopa levels. 
 
6.7.1 Clinical implications 
The findings from the present study raise the possibility that long term LCIG therapy 
can improve the pharmacodynamics of levodopa.  Specifically, the fact that hand 
tapping speed was maintained despite low plasma levels of levodopa suggests that the 
LDR response may have be re-established with LCIG therapy. 
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Conclusions 
This thesis has provided significant insights into the significance of cortical 
excitability changes in both SMS and PD.   
In SMS, SICI was markedly reduced despite the patients still being on high doses of 
benzodiazepines but there was dissociation between measures of cortical 
hyperexcitability, spinal hyperexcitability, serum anti-GAD antibodies and clinical 
symptoms in stiff man syndrome.  The results suggest that spinal hyperexcitability 
and muscle stiffness and spasms are unlikely to be simply due to cortical disinhibition 
of spinal circuits.  This study highlights the current incomplete understanding of the 
pathophysiology of SMS.  Further studies of the relationship between cortical 
excitability and other features of SMS such as associated psychiatric symptoms, as 
well as studies of the relationship between cortical excitability, brainstem excitability 
and features of SMS may give further insights into the pathophysiology and treatment 
of SMS. 
In PD, the most significant finding was that relatively advanced PD patients treated 
with LCIG tended to have greater reduction in SICI than those with milder disease.  
Additionally, there was a strong positive correlation between plasma levodopa level 
and SICI such that there was progressive reduction in SICI together with plasma 
levodopa level in the OFF-LCIG phase, suggesting that SICI is influenced by the 
severity of disease and drugs used to treat the disease.   Results from studies in 
Chapters 4 and 5 suggest that SICI may be a compensatory phenomenon and notably 
the fact that there was positive correlation between decrement in hand tapping speed 
and SICI suggest that SICI tends to be reduced on those with less decrement perhaps 
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as a compensatory mechanism but normal in those with greater decrement suggesting 
failure of compensatory mechanism.  
The studies and results contained herein confirm there is much value in further careful 
research of cortical excitability changes in Parkinson’s disease and other related 
movement disorders. 
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